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ABSTRACT 
 
 
The supply of nutrients and the removal of waste products play a major role in 
tissue engineering. From all the nutrients necessary for cells seeded on scaffolds for tissue 
regeneration, oxygen is the limiting component due to its low solubility in culture media 
while cells consume five to six moles of oxygen for every mole of monosaccharide.  The 
aim of the present work was to develop different strategies to improve the supply of 
oxygen to human coronary artery smooth muscle cells (HCASMC) seeded on three 
dimensional (3D) porous biostable polyurethane scaffolds. As a springboard for the study, 
the measured value of oxygen diffusivity through porous polyurethane scaffolds, 
fabricated by using pressure differential/particulate leaching technique, was used to 
screen the best polymer concentration. Scaffolds fabricated form 15 wt% polymer 
concentration not only had higher oxygen diffusivity but also have better pore 
interconnectivity as shown by SEM image analysis. Moreover a convective mass transfer 
approach showed an improvement in the infiltration of HCASMCs into the 3D scaffolds. 
An oxygen carrier molecule, perfluorodecalin (PFD), was found to improve dissolved 
oxygen concentration in culture media. PFD was shown to be not only non-toxic to 
HCASMC but also have no significant effect on the morphology of the HCASMCs. 
Therefore, higher cell density and infiltration depth into the polyurethane scaffolds were 
observed when HCASMCs were cultured in a media containing PFD. The final stage of 
this work was to introduce an oxygen vector into the skeleton of polyurethane scaffolds. 
For this reason, inert Zeolite Y particles were fluorinated and shown to enhance the 
amount of dissolved oxygen when suspended in culture media.  Fluorinated Zeolite (FZ) 
 
iv 
 
 
particles were then embedded into polyurethane scaffolds without modifying the porosity 
and morphology of the 3D structures. Subsequently, higher cell density and infiltration 
depths were observed when HCASMCs were cultured on FZ particles embedded 
polyurethane scaffolds in contrast to bare polyurethane scaffolds. Taken together, these 
data show three different but equally advantageous strategies of improving the supply of 
oxygen to HCASMC seeded into the interstices of 3D polyurethane scaffolds.    
 
Keywords: Tissue engineering, polyurethane scaffolds, vascular grafts, oxygen 
diffusivity, vascular smooth muscle cells, oxygen carrier molecules, perfluorodecalin, 
fluorinated Zeolite particles, cell proliferation, cell infiltration,  
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CHAPTER 
         1       
       
1 INTRODUCTION 
 
1.1 Overview 
Cardiovascular disease such as coronary artery occlusion is one of the leading causes of 
death in both Western and non-Western societies.1 Conventional severe medically 
refractory coronary and peripheral artery diseases treatment options such as the use of 
autologous vessels and prosthetic grafts have suboptimal performances.2, 3 Over the past 
15 years, the concept of vascular tissue engineering, representing an interdisciplinary 
effort with considerable potential to treat vascular disease, has emerged to be a viable 
treatment alternative.4 The strategies of in vitro tissue engineering are conceptually 
simple and clinically appealing yet these have proven to be a formidable engineering task. 
Despite rapid advances made in this field, success is still limited due to significant 
knowledge gaps in our ability to regulate tissue formation. Within the context of 
engineering, providing sufficient oxygen mass transport that is vital for cellular 
metabolism is perhaps one of the unmet challenges to fabricate tissues of clinical 
relevance.5, 6 It has long been known that the supply of oxygen and soluble nutrients 
becomes critically limiting for the in vitro culture of 3D tissues.7 The consequence of 
such a limitation is exemplified by early studies showing that cellular spheroids larger 
than 1 mm in diameter generally contain a hypoxic and necrotic center surrounded by a 
rim of viable cells.8 Similar observations beyond depths of 250 µm were reported for a 
   2  
 
number of cells cultured on 3D scaffolds where a non-homogenous cell distribution is 
reported.9-11 Because engineered blood vessels should be at least 500 µm in wall 
thickness, mass transfer limitations represent one of the challenges to be addressed for 
cell survival. 
 
Unlike what is described above, in vivo mass transfer requirements are facilitated by 
convective transport of hemoglobin-bound oxygen to tissues to the proximity of 
capillaries. In most tissues, cells are no more than 100 µm from these capillaries allowing 
sufficient oxygen to be delivered. The small diameter of capillaries (between 6 and 8 µm) 
ensures a residence time long enough in tissues to permit the radial diffusion of chemical 
species 12. Thus in vivo, cells are constantly perfused with the flowing blood through the 
vasculature. At lower blood plasma concentrations of oxygen in tissues, oxygen 
dissociates from hemoglobin and diffuses into tissues and cells. As the blood vessels 
themselves are made up of cells, they too require sufficient oxygen and nutrients to 
survive. Since the wall of the larger blood vessels is too thick to allow diffusion between 
the blood stream and surrounding tissue of the wall, the adventitial layer of these vessels 
contains small arteries called vasa vasorum that supply the smooth muscle cells and 
fibroblasts within the media and adventitia their nutrient demand. Therefore mass transfer 
within the vascular wall is facilitated by the diffusion of oxygen both from the lumen and 
adventitial side.  
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1.2 Thesis Outline 
In view of the above brief overview, the work presented in this thesis underscores the 
importance of addressing oxygen mass transfer to design and fabricate vascular tissues of 
clinical relevance.  In Chapter 2, pertinent literature review is presented. Although the 
open literature documented far exceeded those cited in this thesis, an effort was made to 
focus on recent advances while equally acknowledging seminal works in the field. In 
Chapter 3, scaffold fabrication, diffusion measurements, and some cell culture data are 
presented. Chapters 4 and 5 describe two different approaches chosen to enhance oxygen 
mass transfer in 3D cell cultures each with specific objectives.13, 14 Finally, the 
significance, contributions, and limitations of the study are presented in Chapter 6.  
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CHAPTER 
         2       
  
2 LITERATURE REVIEW 
Overview: This chapter provides background information on the physiology and diseases 
of coronary arteries, surgical interventions and the need for and the challenges of tissue-
engineered vascular substitutes. Elements of vascular tissue engineering are presented 
with a focus on the delivery of oxygen to engineered tissue constructs. It concludes with a 
statement of study rationale and an outline of specific hypotheses and objectives of this 
study. 
2.1 Anatomy and Physiology of Coronary Arteries  
Coronary arteries, which are the first to branch off from the ascending aorta, supply blood 
to the heart muscle. Both the right and left coronary arteries extend from the aorta to the 
heart walls supplying blood to the atria, ventricles, and septum of the heart. Coronary 
arteries are composed of three concentric tunics (Figure 2.1). The tunica intima forms the 
innermost lining composed of non-thrombogenic monolayer endothelial cells. By 
secreting specific molecules such as nitric oxide, endothelial cells inhibit platelet 
activation and prevent thrombus formation.1, 2 The tunica media is generally composed of 
a dense population of concentrically organized smooth muscle cells and is separated from 
the tunica intima by an internal elastic lamina.3 Under physiological conditions, smooth 
muscle cells possess a quiescent contractile phenotype and control the dilation and 
constriction of blood vessels thus regulating blood flow. Under pathological conditions, 
smooth muscle cells convert to a synthetic and non-contractile phenotype. This synthetic 
phenotype results in the proliferation and increased matrix production in the tunica media 
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resulting vessel stenosis.4 The tunica adventitia (externa) forms the external layer and 
contains a collagenous extracellular matrix and fibroblast cells. Ultimately, tissue-
engineered blood vessels should contain all of these layers for proper functionality.  
 
Figure 2.1: Schematic representation and histology of coronary artery wall 
structure.5  
   7  
 
2.2 Coronary Artery Diseases 
Coronary artery disease is the most common form of heart disease. Atherosclerosis, 
characterized by a progressive accumulation of lipids and fibrous elements in the lumen, 
is a widely recognized inflammatory disease affecting the vasculature (Figure 2.2). The 
early lesions of atherosclerosis consist of sub-endothelial accumulations of cholesterol-
engorged macrophages, called 'foam cells' which acts as preferred sites for lesion 
formation.  
 
Figure 2.2: Schematic representation of normal and diseased arteries. 
With time, the lesions grow and will reach a point where the artery is so narrow that 
blood flow becomes insufficient to supply the succeeding vessels leading to angina and 
ischemia. The deprivation of blood results in oxygen deficiency in the myocardium, and 
accumulation of carbon dioxide and lactic acid in the tissue.6 Unstable lesions with a thin 
fibrous cap are highly susceptible to plaque rupture and erosion, exposing the necrotic 
core and potentially leading to the formation of a thrombus. Thrombosis results in acute 
artery occlusion leading to potentially fatal heart attack.7 In addition to inflammatory 
   8  
 
atherosclerotic lesions, congenital anomalies of the coronary artery are found in 1-2% of 
the population.8-10  While the majority of these anomalies do not result in signs, 
symptoms or complications, others such as coronary atresia, coronary hypoplasia, single 
coronary artery and ectopic coronary origin are associated with serious events such as 
myocardial infarction, cardiac arrhythmias, syncope, congestive heart failure and sudden 
death.11-13 
2.3 Surgical Intervention 
In the early stages of the plaque build-up, a minimally invasive coronary balloon 
angioplasty intervention technique is a preferred method to surgery for reopening 
occluded atherosclerotic vessels. Following the intervention, stents are often deployed to 
prevent elastic recoil of the vessel wall.14 However, for advanced atherosclerotic lesions, 
coronary artery bypass grafting (CABG) is the only alternative. Autologous grafts remain 
the primary choice for CABG because of their compliance, immune acceptance, and non-
thrombogenicity. The most commonly used autograft  is the saphenous vein (SV) 15 but 
the internal mammary artery and radial artery are also used.16  The extensive use of SV as 
CABG  is, in part, because it is surgically easier to access and harvest.17 However, its 
performance is not sufficient in large due to the gradual deterioration when exposed to 
high-pressure arterial sites leading to excessive dilation and also due to a combination of 
intimal hyperplasia and accelerated atherosclerosis.18-22 Therefore, further surgical 
revascularization is often required in about 10 years after the initial bypass surgery but the 
availability of SV for second and third bypass surgery is a limitatition.23   
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Even though the preferred bypass vascular substitute is the patient’s own arteries or veins, 
they are generally inadequate or unsuitable for approximately one-third of patients 24, 25 
suggesting the obvious need for alternative grafts.26 Prosthetic grafts have been developed 
as an alternative to autografts and, the most commonly used materials are polyethylene 
terephthalate (PET, Dacron®) and expanded polytetrafluoroethylene (ePTFE, Teflon®). 
Dacron® and Teflon® have been used successfully in the replacing large arteries, 
however, when the vessel diameter is under 5 mm, the clinical outcome is 
disappointing.27, 28 The low patency of synthetic grafts in small diameter artery 
reconstruction is due to lower blood flow velocities resulting from intimal hyperplasia at 
the anastomotic site.13 The development of intimal hyperplasia is attributed to the 
compliance mismatch between the graft and the native vessel, and the thrombogenecity of 
the synthetic surface.29, 30 The difference in elasticity at the anastomotic site creates 
turbulence in the blood flow and damages the endothelial lining, resulting in thrombus 
formation and compliance mismatch as shown in Figure 2.3.31, 32 In order to avoid these 
complications, patients having prosthetic grafts often require extensive anticoagulant 
medications.    
 
Figure 2.3: Schematic drawing showing the compliance mismatch between the 
native tissue and a prosthetic graft leading to hemodynamic changes and thrombus 
formation. 
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In addition to Dacron® and Teflon®, polyurethanes have been tested as vascular graft 
materials due to improved compliance, thromboresistance, and reduced anastomotic 
hyperplasia. 33  Polyurethanes are also reported to promote the ingrowth of living tissues 
in and around the grafts potentially modifying the initial compliance of the graft. 34, 35 
However, their clinical use as prosthetic grafts was limited due to their poor biostability. 
36, 37 To overcome these issues, a newly developed polyurethane graft based on 
polycarbonate soft segment showed improved resistance to biodegradation for a 3 year 
period in a canine model. 38, 39 The presence of the polycarbonate soft segment is 
responsible for the increased resistance to biodegradation in comparison to other soft 
segments. 
2.4 Engineered Vascular Tissues as Functionally Competent Conduits 
As stated above, the disappointing outcome of synthetic vascular grafts and the limited 
supply of autogafts necessitate tissue engineering approaches for constructing autologous 
vessels. Vascular tissue engineering technology holds promise in the design of responsive 
living conduits with properties similar to those of the native tissue40. In tissue engineering 
of blood vessels, synthetic biodegradable, non-degradable or ECM scaffolds are 
infiltrated with vascular cells and cultured under physiological conditions to mature 
before implantation into the patient41-43 (Figure 2.4).  
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Figure 2. 4: Schematic processes in tissue engineering showing the essential stages in 
tissue fabrication 
Tissue-engineered blood vessels thus have specific advantages since they are designed to 
be responsive both mechanically and biologically with respect to the load that changes 
with the hemodynamic environment. The first clinical application of a tissue-engineered 
vascular construct was reported in 2001 for a paediatric patient with congenital single 
ventricle cardiac anomaly.41  This was an exceptional case because no synthetic graft 
could be used with the capacity to grow, repair, and remodel as required with normal 
development. Since then, tissue-engineered conduits have been used for a total of 25 
extracardiac cavopulmonary connections (median patient age 5.5 years) with only two 
late cardiac failure deaths reported.44-47 The success of this procedure can be partially 
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attributed to the relatively low-pressure environment (20 to 30 mmHg during systole) 
found in pulmonary circulation, which is less demanding than pressures found in 
coronary arteries (100 to 140 mmHg during systole). Despite the urgent need for an 
engineered vascular tissue substitute, success is still limited.48 While engineering 
approaches for other tissue substitutes can rely on in vivo remodelling to approach 
functionality with time, tissue-engineered blood vessels must function immediately on 
implantation − a significant challenge that contributed to its limited success.49 The long 
lead time associated with the fabrication of an autologous vascular substitute is 
commonly invoked as a major limitation to widespread clinical use. While this point may 
be valid for emergency coronary artery surgical procedures or critically ischemic limbs, 
in practice, most coronary and distal vascular bypass procedures can be predicted and 
delayed over extended periods, allowing sufficient time for tissue fabrication.48 
Clinical trials of engineered vascular substitutes for the adult population has been initiated 
to examine the use of these grafts as arteriovenous shunts, as well as coronary and lower 
limb bypass grafts.48 The initial clinical trial was focused on the safety of the 
arteriovenous shunt model due to the lack of suitable vein for hemodialysis and the 
deplorable efficacy of synthetic vascular grafts. Although graft failure in this model is 
unlikely to be life or limb-threatening, the high flow rates encountered (ca. 800 ml/min) 
generate considerable hemodynamic loads.48 Notwithstanding both technological and 
regulatory challenges that lie ahead, engineered vascular tissues continued to be the "holy 
grail" of future vascular intervention.50  
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2.5 Engineered Vascular Tissues as Species-specific Predictive Organ Model 
The use of vascular cells and whole sections of a harvested artery in combination with 
animal models to study vascular diseases (e.g. atherosclerosis, post angioplasty restenosis, 
and hypertension) in an attempt to develop therapeutics is not new but employing 
engineered human vascular tissues for this role is a novel concept.51 While conventional 
2D cell cultures are indispensable to our understanding of tissue morphogenesis and 
function in physiological and pathological states, they do not accurately replicate the 3D 
microenvironment of human tissues.52 For example, 2D culturing of vascular cells for 
studying intimal hyperplasia without the arterial wall structure and extracellular matrix 
(ECM) cannot recapitulate the intricate vascular wall mechanics and morphogenesis.53 
Similarly, animal organ cultures and whole animal models do not completely mimic the 
human biology due to the inevitable inter-species difference.54 Studies using closely 
related nonhuman primates are constrained by limited availability, legal restrictions, 
ethical concerns, and high cost making these animal models impractical.55  When 
studying human vascular diseases and therapeutics, a realistic model is a human tissue but 
the inability to experiment directly on human subjects limits this progress. Thus the need 
for an engineered human vascular tissue model to close this gap is of vital importance. 
Engineered human vascular tissues are not likely to replace animal or human subjects; 
however, they have the potential to provide high throughput, substantive, and detailed 
information regarding very specific conditions under controlled environments to study 
disease models and therapeutic outcomes that are not possible with animal-based model. 
The impact of successfully engineered human tissues is, therefore, not only restricted to 
the clinic but also fills a critical gap in the pre-clinical model tool chest between 
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traditional cell culture and whole animal experiments and has the potential to accelerate 
the pace of basic biomedical research.56 A number of important physiological 
characteristics of native tissues appear to be preserved in an engineered tissue; thus 
providing models for specific disease conditions such as elevated contractility of vascular 
smooth muscle cells in hypertension, elevated proliferation in atherosclerosis and post-
angioplasty restenosis and, fibrosis and cardiovascular remodeling.57-61 In this context, 
engineered vascular tissue technology may be used both to validate drug targets and to 
optimize loads. This allows for cardiovascular drug screening in a more controlled and 
efficient way than can be performed using a traditional whole animal approach, thereby 
minimizing the number of laboratory animals used and decreasing the overall cost of 
performing research.56  In recent years, engineered 3D tissue models such as cardiac 
patch62, lung tissue63, cornea64 and solid tumor65, 66 have emerged as powerful tools for 
drug discovery. Although clinical applications of engineered 3D tissues attracted most 
media attention, it is evident that engineered tissue models can serve as platforms for 
tightly controlled, high-content screening of drugs and for pharmacodynamic analyses. 
2.6 Engineered Vascular Tissues in Physiological Genomics Studies 
Physiological genomics is an emerging field that brings together the disciplines of 
genomics and cell, organ and whole animal systems integrative physiology in an effort to 
to link gene products and pathways to phenotypes and physiological systems.56, 67 
Physiological genomics study has traditionally been costly, requiring significant time to 
breed and age animals before initiating expensive and time-consuming phenotyping 
protocols.56 Towards this end, the use of in vitro fabricated 3D tissue systems to reduce 
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the cost and time required for physiological genomic research is a relatively unexplored 
concept (Figure 2.5).   
 
Figure 2.5: Engineered tissue provides an opportunity for obtaining a wide variety 
of phenotypes previously restricted to whole animal studies, including mechanical 
measurements such as force of contraction, in an environment that more closely 
replicates complex native tissue than 2D cell culture. This approach also captures 
practical advantages of 2D culture, including the ability to make high-throughput 
measurements and efficiently manipulate genomes. This unique model has the 
potential to provide a link between whole animal and traditional culture approaches 
to studying physiological genomics.56 
Recent progress in miniaturizing engineered tissues and associated physiological assay 
systems will accelerate our knowledge about interaction of the genome with both the 
phenome and the environment.56  For example, using DNA microarrays with 9600 genes, 
Chien and coworkers68 demonstrated that 77 vascular smooth muscle cells (VSMCs) 
genes were expressed more than twofold and 22 genes were expressed less than one-half 
in 3D matrix when compared with the 2D culture condition.  Specifically, cells in 3D had 
less stress fibers and focal adhesions, and a lower level of tyrosine phosphorylation of 
focal adhesion kinase. The cyclin-dependent kinase inhibitor 1 (p21) was differentially 
upregulated in 3D leading to lower VSMC proliferation. Collagen I expression was also 
higher in 3D suggesting that VSMCs cultured on 3D matrix have increased ECM 
synthesis. In addition, Mequanint and coworkers69 showed upregulation of the elastin 
gene and downregulation of VSMC differentiation marker genes when cultured on 3D 
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scaffolds compared with 2D surfaces. Differential gene expression is not limited to 
vascular cells. Several groups have reported preliminary evidence that gene expression of 
different cells cultured in 3D parallels more closely the in vivo situation.70 Gene 
expression profiling experiments in various cell types clearly demonstrated close 
correlation between engineered and native tissues in tumor cells71, tendon72, bone73, and  
skin74. Collectively, these studies point to engineered tissue as a model system that could 
be used to test gene expression and study the effect of altered gene expression on function 
in vitro. In summary, successful application of these strategies may, in the near future, 
allow investigators to identify the gene or genes responsible for a phenotype or disease 
state in 3D culture rather than depending on the traditional positional cloning approach, 
which often requires years of painstaking breeding and phenotypic studies.56 
2.7 Essential Elements of Tissue Engineering  
For tissue engineering to become a broadly accepted alternative for the treatment of 
diseased or otherwise compromised tissues and organs there are a number of critical 
elements that must still be addressed (Figure 2.6). These elements cover cell biology, 
materials design, bioprocess engineering, and clinical outcome.  In the following sections 
each of the elements will be briefly discussed.  
   17  
 
 
Figure 2.6: Essential elements in tissue engineering.75 The fabrication of tissue-
engineered products that meet the needs of clinical efficacy, quality, and regulatory 
requirements, manufacturing facility, and viable distribution mechanism requires 
expertise in each of several basic areas of research and development. These include 
cell sourcing and expansion, designing of biocompatible scaffolds that meet in vitro 
and in vivo tissue growth demands, designing bioreactors and large-scale 
manufacturing and preservation systems to enable cost-effective production and 
distribution. Finally, strategies for solving immunological issues must be developed. 
2.7.1 Cell Sourcing 
In order to engineer a tissue, cells are undoubtedly the starting point that needs to be 
considered.  For vascular tissue engineering, the two main cell types needed are VSMCs 
and endothelial cells (ECs).  VSMCs constitute the main cellular components of the 
tunica media of arterial vessels. In a mature artery, they display a contractile phenotype 
with a very low proliferative activity and produce only small amounts of ECM proteins 76 
while expressing contractile cytoskeletal marker proteins such as smooth muscle α-actin 
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(SM-α-actin), smooth muscle myosin heavy chain (SMMHC), smoothelin-B, h-
caldesmon and calponin; and contract in response to electrical, chemical and mechanical 
stimuli.77, 78 However, VSMCs may also acquire a synthetic phenotype and become 
predominantly proliferative if stimulated under certain biochemical and biomechanical 
conditions. In the synthetic phenotype, VSMCs suppress the expression of genes that 
define the contractile phenotype while rapidly upregulating genes required for 
proliferation including matrix metalloproteinases and l-caldesmon.4, 79-82 During 
vasculogenesis, VSMCs exist largely in the synthetic phenotype and synthesize ECM 
proteins such as elastin, collagens and glycosaminoglycans.83 This phenotype modulation 
is useful to engineer vascular substitutes. VSMCs can be sourced from either the patient 
or a donor but the use of autologous cells is preferable since xenogenic and allogeneic 
cells introduce potential risks for immunorejection.84, 85 One limitation of patient-specific 
differentiated VSMCs is, however, their limited proliferative ability that results in 
extended time for cell expansion.86-88 In order to overcome senescence, ectopic 
expression of telomerase via human telomerase reverse transcriptase (hTERT) gene 
transfection of adult VSMC has been studied.89, 90  Despite robust cell growth that 
populated the scaffolds and resulted in a thick wall of the engineered artery, several issues 
related to the safety of telomerised cells need to be resolved before these cells are 
recommended for tissue engineering. For example, transfection with hTERT might lead 
to uncontrolled growth leading to intimal hyperplasia and possibly tumor development.91 
Recent advances in sourcing VSMCs for fabricating vascular tissues have shifted towards 
stem cell niche with considerable success.92-96 Although VSMCs are the most studied in 
the context of engineered tissue fabrication, ECs play a significant role for the overall 
function of the engineered tissue. As such, a quiescent EC monolayer that regulates 
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contractile VSMCs phenotype is an important requirement for functional tissue-
engineered vascular substitutes.97 ECs have a dynamic nature and interact with the 
underlying VSMCs through direct cell-cell contact or through the synthesis and release of 
mediators into the surrounding medium.98   In this thesis, human primary coronary artery 
smooth muscle cells are used.  
2.7.2 Scaffolds  
With the exception of some studies 99-101, porous scaffolds which mimic the extracellular 
matrix, are required for the 3D growth of cells to form engineered constructs.46, 102 
Depending on the intended application, scaffolds may be designed to be biodegradable so 
that only the native tissue will remain after a given period of culture time or it may be 
biostable such that a composite tissue that provide long-term support could be 
fabricated.42, 46, 103-105 In the case of biodegradable scaffolds, cells will remodel the 
scaffold with their own ECM proteins creating the intended tissue without compromising 
tissue structural integrity. This, however, requires strict coordination of the scaffold 
biodegradation rate with the biosynthetic rate and is one of the major obstacles in the field 
today. In addition, a scaffold must have several required characteristics: biocompatibility, 
appropriate mechanical strength and compliance, optimal porosity for cell seeding, in 
vitro nutrient and oxygen transport, and the ability to bind to cells and release growth 
factors when needed.  Although some of these criteria could be met with existing 
scaffolds, they do not provide biological cues for the cells imbedded in them and do not 
interact with the cells. In the body, cells reside within the ECM, which provides tissues 
with the appropriate architecture as well as signaling pathways that influence key cell 
function such as migration, proliferation, and differentiation. Regeneration of tissues in 
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vitro thus requires that cells be given a more specific level of instruction so that tissue 
regeneration is successful. With the discovery of cell adhesion peptide domains in 
fibronectin, collagen and laminin, the design of synthetic extracellular matrices with 
biological activity has become an area of intense research activity.106-108 Scaffolds affect 
cellular functions such as adhesion, migration, proliferation, differentiation and secretion 
of ECM components.69 
2.7.3 Bioreactors 
 A bioreactor is a dynamic in vitro environment that uses both biochemical and 
mechanical signals to guide and regulate tissue developments.109 The concept of 
bioreactors is neither new nor restricted to tissue engineering since cultivating proteins 
from microbial or mammalian cells for therapeutic or diagnostic applications is well-
known.110, 111 They have been developed in response to static culture limitations and are 
used to distribute cells uniformly on 3D scaffolds, provide the desired concentrations of 
gases and nutrients in the culture medium, maintain efficient mass transfer to the growing 
tissue, and apply a physical stimuli to the developing tissue.112, 113 Several bioreactor 
designs such as rotating-wall, spinner flasks, and perfusion have been developed to 
engineer a variety of tissues (Figure 2.7). In order to properly simulate physiological 
conditions, vascular tissue engineering requires a system that mimics the hemodynamic 
forces experienced by vascular tissues. These mechanical forces include shear stress and 
stresses in the radial, circumferential and longitudinal directions. Shear stresses are 
tangential frictional forces that are directly perceived by endothelial cells and indirectly 
transmitted to smooth muscle cells as a result of interstitial flow and signalling.114-118 
Initial attempts to create engineered blood vessels resulted in the manufacturing of grafts 
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with poor mechanical properties.119 The next generation of tissue engineered vascular 
substitutes had dramatically improved mechanical properties; however, it took several 
months to develop tissue engineered vascular grafts with desired optimal mechanical 
properties.100 Because elastin and collagen are the main two components of ECM that 
determine the biomechanical properties of vascular tissues, dynamic mechanical 
conditioning of the construct accelerates the production of these two proteins. For 
example, the periodical radial distention resulted in accelerated maturation of engineered 
vascular tissues.120, 121 In an in vitro experiment with a rabbit pulmonary artery subjected 
to longitudinal stretch, the rate of elastin and collagen synthesis was related to the 
magnitude of the longitudinal stretch.122 It has been also reported that endothelial cell and 
smooth muscle cell proliferation rates in rabbit carotid arteries increased 50-fold and 15-
fold respectively after three days of longitudinal stretch in vivo.123 These data indicate 
that longitudinal stretch of arteries is an important mechanical force for accelerated cell 
proliferation, production of the ECM, and vascular remodeling.  
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Figure 2.7: Summary of different bioreactors used for tissue fabrication.  
The importance of mechanical forces on developing engineered vascular tissues is not 
fully understood. Most cells persist in the state of dynamic flux where gases and 
diffusible molecules may interact, either directly or indirectly as ligands by binding 
specific receptors on the cell surface, and thus modulating cellular phenotype.124-126 Shear 
forces act in a variety of different ways by acting on the endothelial cell membrane, thus 
indirectly affecting the cell, by acting on the cell as a whole, or by stressing specific 
molecules integrated into the cell membrane and transmit directly via transmembrane 
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proteins connecting to the cells interior organelles or indirectly through cell signalling 
cascades which lead to change in gene expression.21, 127, 128 
Blood vessels are permanently subjected to mechanical forces in the form of stretch, 
encompassing cyclic mechanical strain due to the pulsatile nature of blood flow and shear 
stress. Blood pressure is the major determinant of vessel stretching. It creates radial and 
tangential forces which counteract the effects of intraluminal pressure, and which affect 
all cell types in the vessel. In comparison, fluid shear stress results from the friction of 
blood against the vessel wall, and it acts in parallel to the vessel surface. Accordingly, 
shear is sensed principally by endothelial cells located at the interface between the blood 
and the vessel wall.129 Alterations in stretch or shear stress invariably produce 
transformations in the vessel wall that will aim to accommodate the new conditions and to 
ultimately restore basal levels of tensile stress and shear stress  Hence, while acute 
changes in stretch or shear stress correlate with transient adjustments in vessel diameter, 
mediated through the release of vasoactive agonists or change in myogenic tone, 
chronically altered mechanical forces usually instigate important adaptive alterations of 
vessel wall shape and composition. The concept of vascular remodelling has therefore 
been used to describe these transformations that occur in vessels undergoing mechanical 
stresses.126, 130 
2.8 Oxygen Mass Transfer in Tissues  
2.8.1 The Challenges of Oxygen Transfer in Engineered Tissues 
 As discussed above, bioreactors have been developed with the intent to mechanically 
stimulate the growing tissue constructs with physiologically relevant forces and to 
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improve mass transfer within the tissue. Although the former is largely successful, the 
later has shown to be a formidable engineering task. Therefore the delivery of nutrient 
and the removal of metabolic waste materials remained to be a fundamental consideration 
for fabricating engineered tissues. Oxygen delivery, in particular, is a limiting step for 
clinically-relevant size tissues because of it is low solubility in culture media. This is 
further exacerbated by the fact that cells consume five to six moles of oxygen per mole of 
monosaccharide 131-133 according to the following mole balance. 
C6H12O6 + 6O2→6CO2 + 6H2O 
Clearly, the delivery of this much oxygen to cells required the development of oxygen 
delivery system that is more efficient than molecular diffusion alone.  
2.8.2 In Vivo Oxygen Transfer  
In vivo, the above-mentioned limitation is mitigated by two specialized systems. First, the 
presence of the circulatory system carries the oxygen in blood by convection (Table 2.1) 
to the capillaries that are closer to the cells facilitating oxygen diffusion over shorter 
distances.  
Table 2. 1: Peak convection rates of blood in the vasculature.134 
Compartment cm/sec 
Aorta 140±40 
Common carotid 100±20 
Vertebral 36±9 
Femoral 90±13 
   25  
 
However, at an arterial pO2 (100 mmHg), only 0.3 ml oxygen dissolves in 100 ml plasma. 
Given that a human body needs 250 ml oxygen per minute,134 plasma-dissolved oxygen 
contributes only to 15 ml/min at a cardiac output of 5 L/min. In the absence of an oxygen 
carrier, this translates to a cardiac output of 83 L/min which is impossible. This limitation 
is addressed by a second specialized system in which the oxygen carrier protein, 
hemoglobin, overcomes the very low solubility of oxygen in plasma.  
2.8.3 The Oxygen-hemoglobin Dissociation Curve  
The cooperative binding of oxygen to hemoglobin is described by the oxygen-
hemoglobin dissociation curve. This is an equilibrium curve that expresses the fractional 
occupancy of the hemoglobin oxygen binding sites (Y) at a given oxygen partial pressure 
(pO2) (Figure 2.7).  
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Figure 2.8: Changes in the oxygen-hemoglobin dissociation curve.135 A shift to the 
right is often caused by increased CO2 concentration or a decreased pH. The 
opposite is true for the shift to the left.  
The equilibrium oxygen partial pressure above the solution of blood is related to the 
dissolved oxygen concentration by Henry’s law. 
2yP pO C≡ = Η                   (1) 
In the above equation, H is the Henry constant, which is mmHg0.74
μM
 
 
 
 for oxygen, C is 
the dissolved oxygen concentration (µM) and y is the mole fraction of oxygen in the gas 
phase. It will be important to realize that the pO2 is exerted only by the dissolved oxygen. 
The oxygen bound to the hemoglobin does not affect pO2 but serves only as a source for 
oxygen. With this in mind, hemoglobin bound oxygen is transported by the circulatory 
system to the capillaries where a change in the pO2 levels along the length of the capillary 
causes oxygen to be released. This released oxygen then diffuses across the capillary wall 
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to reach the cells. The binding and releasing of oxygen to hemoglobin is represented by 
Hill’s equation. 
2 n 2Hb(O ) Hb + nO↔                   (2) 
[ ] [ ] [ ][ ]1 2 1 2( )
n
n
d Hb
k Hb O k Hb O
dt −
= −               (3) 
Where k1 and  k-1 are the association and dissociation rate constants respectively. 
The overall equation can also be written as: 
[ ] [ ][ ]2 2 1 1( )  ; where   /
n
nHb O k Hb O k k k−= =               (4) 
The oxygen demand of a tissue can be calculated through the basic material balances on a 
controlled volume. Let Г represent the tissue metabolic volumetric oxygen consumption 
rate in 



sec
Mµ , Vt is volume of the tissue space (including the capillaries), q is the tissue 
blood perfusion rate (mL of blood /cm3 tissue/min), C is dissolved oxygen in plasma 
(μM), C' the concentration of oxygen in the blood that is bound to the hemoglobin (μM), 
Ct represents the concentration of oxygen dissolved in the interstitial space of the tissue 
(μM), Pc represents the permeability of oxygen through the capillary wall and Sc 
represents the total surface area of the capillaries (cm3). The mass balance in the blood 
will be: 
 0 ( ') ( ') ( )A V c c v tqV C C qV C C P S C C= + − + − −             (5) 
Whereas the mass balance in the tissue is: 
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 0 ( )c c v t tP S C C V= − − Γ               (6)   
Combining equations (5) and (6) the metabolic oxygen consumption is given by, 
            [ ]( ') ( ')A Vq C C C CΓ = + − +               (7) 
At the normal tissue perfusion rate of 0.5 ml of blood /cm3 tissue/min, taking the partial 
pressure of oxygen in arterial and venous blood to be around 100 and 40 mmHg 
respectively, and assuming the density of the tissue ~1g/cm3, Г will be 23 / secMµ . The 
experimentally measured average body oxygen consumption value reported in the 
literatures is in the order of 20 / secMµ  which is in good agreement with the predicted 
value. 136 
2.8.4 Alternative Oxygen Binding Chemicals 
The search for alternative oxygen binding chemicals has been and still remained to be an 
active area of research.137 From a clinical standpoint, this has been fuelled by increasing 
negative public perceptions about blood safety coupled with the potential risk of 
transmitting diseases due to transfusion.138, 139 The use of a blood substitute during 
surgery will reduce patient exposure to donor blood, thereby minimizing disease 
transmission and preventing other unwanted transfusion-related complications especially 
immunomodulatory reactions.139 Alternative oxygen binding chemicals broadly fall in 
one of two categories: i) modified hemoglobin derived either from human and animal 
sources and crosslinked to improve intravascular persistence times or engineered 
genetically using recombinant technology.140, 141 ii) synthetic, inert, perfluorinated 
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compounds (PFC).142 Due to the relevance of PFCs to the work in this thesis, pertinent 
review is presented in the following section.  
2.9 The Chemistry of Perfluorocarbon Compounds 
PFCs are organic compounds whose hydrogen atoms in the carbon network are replaced 
by fluorine atoms. There is no surprise that replacing all the hydrogen atoms by fluorine 
in an organic molecule should bring significant changes in the properties of the resulting 
compound. Since all electrons in fluorine atom are packed in a proportionally less space, 
fluorine has a much denser electron cloud and higher ionization potential compared with 
hydrogen. The thermodynamic stability of PFCs is derived from the enhanced match 
between the carbon and fluorine orbitals as compared to that between carbon and 
hydrogen - leading to the strongest single bond (ca. 530 kJ/mol) found in PFC 
compounds.143 Furthermore, the extreme electron attracting character of fluorine 
enhances the C-C bond energy in the skeleton by "shrinking"’ the orbitals of the carbons. 
These factors are responsible for the inertness of PFCs since there exists no low energy 
molecular orbitals accessible for reaction as the fluorine atoms shield the C-C skeleton 
sterically.143 Given that PFCs are extremely stable and inert to many aggressive 
environments, they are also not metabolized as there are no enzymes able to break them 
down.   
2.9.1 Oxygen Solubility in PFCs 
PFCs have unique characteristics of low water and lipid solubility (i.e hydrophobic and 
lipophobic) but high dissolving power for oxygen and carbon dioxide making them 
attractive for both chemical and biological research.144 Gas solubility is a result of 
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fluorine's low polarizability which translates to low van der Waals intermolecular 
interaction within the PFC molecule.  Since van der Waals interactions are the only 
intermolecular forces that hold non-polar compounds together, these forces are feeble, in 
contrast with their intramolecular bonds. This low cohesive energy density in PFC 
compounds dissolves another low cohesive energy density compound such as oxygen 
(Figure 2.9).  
 
Figure 2.9: Oxygen solubility in different hydrocarbons and fluorocarbons.143 
Oxygen binds to hemoglobin by strong, localized chemical coordinate bond established 
between the oxygen molecule and the iron atom of a heme. In the case of PFC, however, 
there is a physical dissolution of oxygen characterized by loose non-directional van der 
Waals interaction among like materials144. The difference in these interactions reflects the 
difference in oxygen uptake curves as a function of pO2 which is sigmoid for hemoglobin 
and linear for PFC. The linearity is the result of Henry's law in which solubility is directly 
proportional to the gas’s partial pressure, and not a localized chemical binding situation as 
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in hemoglobin. Consequent to this, oxygen can be rapidly and extensively extracted from 
PFCs when needed.  
2.9.2 PFCs as Oxygen Delivery Systems 
Their high oxygen dissolving power and outstanding chemical and biological inertness is 
the basis that made PFCs as candidates for in vivo O2 delivery.143 Although the ability of 
PFC in dissolving larger amounts of gases than any other solvent was already known, 
Clark and Gollan145 were the first to demonstrate that mice could live while breathing an 
O2-saturated liquid PFC without any harm to the animals. As indicated earlier, PFCs are 
both hydrophobic and lipophobic and thus are insoluble in water and lipids - two of the 
most abundant biological fluids. The PFC-water interfacial tension which opposes the 
dispersion of PFCs in water can reach as high as 60 mN/m. In order to effectively use 
them, they must be emulsified  demanding a stable, injectable, small-sized, narrowly 
distributed PFC emulsion (Figure 2.10). The non-ideal nature of the PFC-water solution 
suggests the difficulty to store the emulsion for an extended period of time.  
  
Figure 2.10: Preparation of perfluorocarbon emulsion using surfactants and 
dispersion energy in order to overcome the PFC-water interfacial tension. Terminal 
heat sterilization is achieved in a rotary sterilizer.143 
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The first preparation of a physiologically adjusted PFC emulsion was reported by Sloviter 
and Kamimoto using bovine serum albumin as a surfactant.146 Following this early report, 
a triblock copolymer of poly(ethylene oxide) and poly (propylene oxide), egg yolk 
phospholipids, potassium oleate and fluorinated surfactants or any combination thereof 
have been investigated as emulsifiers.137 Although pure PFCs are not toxic at all, the 
toxicity of PFC emulsions to cultured cells is attributed to the emulsifiers used.  Within 
the context of tissue engineering, PFCs have been shown to enhance oxygen delivery to 
the growing tissue construct, despite some limitation such as droplet settling due to 
density differences.147, 148 
2.10 Diffusion in Porous Media and Its Relevance in Tissue Engineering  
It was stated earlier that one of the essential elements in tissue engineering is a porous 3D 
scaffold with interconnected pores. A porous 3D scaffold mimics the pores present within 
the extracellular fibrous matrix.136 One important parameter in the study of porous 
materials is tortuosity149 which is the ratio of the minimum inter-pore distance between 
two pores to the shortest distance between those pores. The movement of fluid molecule 
in a porous media follows tortuous pathways in the scaffold void space. Fluid flow 
governing equations in porous media can be numerically solved for the individual pores if 
the structures of the pore networks are known. Alternatively, the porous medium could be 
assumed to be a uniform material in a continuum approach and solved by using Darcy's 
law. In this later approach, there are three length scales namely:  the average size (δ) of 
the pore, the distance (L) over which macroscopic change of physical quantities (e.g. fluid 
velocity and pressure) must be considered, and another length ( l ) between L and δ. This 
last length scale is introduced since L is chosen be the characteristic linear dimension of 
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the porous medium (e.g. the size of the scaffold, or the size of the tissue) and is required 
to be at least two orders of magnitude larger than δ.135  To define l , a volume of 
dimension l  in the porous medium is considered. The volume fraction of the void space 
is then the volumetric porosity (ε) and, the volume fraction of the solid phase is equal to 
1- ε. When l  is closer to δ, ε is more sensitive to the value of l . Conversely, when l  is 
selected to be large, the sensitivity decreases. There exists a value of l  beyond which the 
sensitivity is minimal.  In biological tissue mµδ 1.0< , 1l mµ≈  and mL µ100≈  allowing 
transport in biological tissues or scaffolds to be studied with the continuum approach.135 
Fluid transport in scaffolds must also satisfy the conservation of mass. Because both fluid 
production and fluid consumption are present when cells are seeded to scaffolds and 
cultured, the mass balance  
v B Lφ φ∇ = −   (8) 
f B Lvε ϕ ϕ∇ = −   (9) 
Where, v is the fluid average velocity in representative volume, fv is fluid average 
velocity in the volume, Bφ and Lφ are volumetric flow rates per unit volume of porous 
medium in sources and sinks respectively. The values of Bφ and Lφ are determined by 
Starling’s Law. 
v B Lφ φ∇ = −   (10) 
Where Jv is flow rate, S is the surface area, Lp is the hydraulic conductivity, P is the 
hydrostatic pressure and π is the osmotic pressure.  
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It is also possible to express the velocity as follows: 
v K P= − ∇   (11) 
P∇  is the gradient of hydrostatic pressure and K is hydrostatic conductivity. In 
combination with equation (8) 
( ) B LK P φ φ∇ − ∇ = −   (12) 
 Equations (11) and (12) are the governing equations for fluid flow in porous media. The 
scaffolds interstitial space can be considered a network of channels filled with porous 
media. Fluid flow in such channels may be correctly modeled by Darcy’s law. When the 
specific permeability (k) of the porous media is low, equation (12) become the Brinkman 
equation.  
0V V P
K
µµ∇ − − ∇ =  
 
(13) 
These equations were used to model flow behavior in scaffolds and vascular tissue 
engineering bioreactors.150-152 
2.10.1 Squeeze Flow in Porous Scaffolds  
Squeeze flow refers to the fluid flow caused by the relative movement of solid boundaries 
towards each other. The boundaries can be either external or internal for fluid flow in a 
porous scaffold. Squeeze flow is applicable in the interstitial space of vascular tissue 
engineering scaffolds; because it mimics the compliance of the vasculature in response to 
the pulsatile force generated by the heart.153-155  
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Figure 2.11: Squeeze flow model. The two boundaries are moving to each other at a 
velocity of Vh, and the space between them is 2h. 
 
Squeeze flow is best expressed by equation (13). In a cylindrical coordinate there is no 
pressure gradient in z direction and hence 0=
∂
∂
z
P . With this we have:   
2
2 0
r
r
V PV
z k r
µµ
∂ ∂
− − =
∂ ∂
 
 
(14) 
Where k is the specific permeability of the scaffold.  The equation is subject to the 
following boundary conditions: 
hzr
V
=
= 0 , and  
0
0
=
=
∂
∂
z
r
r
V  
The solution for (14) is then 
1 2sinh coshr
z z k PV C C
rk k µ
∂   
= + −    ∂   
 
 
(15) 
1
cosh cosh 1r
k P z hV
r k kµ
−  ∂    
 = −    ∂        
 
 
(16) 
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2
1sinh coshz
k k z h z P PV
r r rk k kµ
−    − ∂ ∂    = − +       ∂ ∂        
 
 
(17) 
In a cylindrical coordinate system, the continuity equation is written as: 
( )1 0r zrV V
r r z
∂ ∂
+ =
∂ ∂
 
 
(18) 
Subject to the boundary conditions
hzhz
VV
=
= , and  
0
0
=
=
zz
V , the solution leads to: 
2
2
1
tanh
hV P P
r r rk k h h
k kµ
 ∂ ∂
= + ∂ ∂    −  
  
 
 
(19) 
Thus solving (19) for the second order differential equation will give the pressure 
distribution as:  
2
ln
4
rP A B r C= + +  
 
(20) 
Using the boundary conditions,  
0
0
=
=
∂
∂
rr
P , and  
Rro
PP
=
=  
2 2( )
4 tanh
h
o
VP P r R
k k h h
k kµ
= + −
  
−  
  
 
 
(21) 
Therefore, equations (19-21) provide the fluid velocity and pressure profiles for a squeeze 
flow. The velocity profile will provide the sheer stress distribution in the scaffold which 
is one of the parameters to be considered in dynamic cell culture experiments. The utility 
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of squeeze flow model has been demonstrated in cartilage, bone, and vascular tissue 
engineering strategies.156-160   
2.10.2 Lattice Boltzmann’s Approach for Porous Fluid Flow  
The Lattice–Boltzmann method with computational fluid dynamics has been used to 
simulate the flow conditions within perfused cell-seeded cylindrical scaffolds.161, 162 
Microcomputed tomography imaging is used to define the scaffold micro-architecture for 
the simulations, which produces a 3D fluid velocity field throughout the scaffold porosity. 
Shear stresses are then estimated at various media flow rates by multiplying the 
symmetric part of the gradient of the velocity field by the dynamic viscosity of the cell 
culture media. The shear stress algorithm was validated by modeling flow between 
infinite parallel plates and comparing the calculated shear stress distribution to the 
analytical solution. The simulation results relating to perfusion experiments gave an 
average surface shear stress to correspond to increased cell proliferation, while higher 
shear stresses were associated with upregulation of bone marker genes. Even though  this 
model has been used for cartilage and bone tissue engineering, it is primarily used to 
compare results obtained for different perfusion bioreactor systems or different scaffold 
micro-architectures and may allow specific shear stresses to be determined that optimize 
the amount, type, or distribution of in vitro tissue growth transport. In particular, it is 
applicable and equally usable in vascular tissue engineering with load applied 
bioreactors.163-165 
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2.11 Summary 
In the preceding sections, literature review pertinent to this thesis is presented. Due to 
rapid advances made in tissue engineering, it was not possible to include all aspects of the 
field. However, every effort is made to ensure that seminal works and significant research 
findings are included, with minimal bias, in this Chapter.  Notwithstanding the different 
challenges and opportunities presented by tissue engineering strategies, this thesis will 
only attempt to address oxygen mass transfer limitations in engineered tissue constructs. 
2.12  Hypothesis and Objectives of the Study 
It is hypothesized that 3D polyurethane scaffolds with interconnected pores enhance 
oxygen diffusivity. It is further hypothesized that oxygen delivery strategies using PFC 
enhances mass transfer and human coronary artery smooth muscle cells (HCASMC) 
infiltration when seeded into 3D polyurethane. In order to test the above hypotheses, the 
following objectives were formulated:  
• Fabricating 3D porous poly (carbonate urethane) (PCU) scaffolds using a pressure 
differential/particulate leaching technique at different PCU concentration.  
• Measuring of effective diffusivity of oxygen through PCU 3D scaffolds 
• Developing a mathematical model for oxygen profile on cell seeded 3D scaffold 
and in the lumen channel. 
• Evaluating the supply of oxygen to HCASMC seeded on 3D PCU scaffolds using 
oxygen carrier particles embedded in the scaffold. 
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CHAPTER 
         3     
 
 
3 TISSUE ENGINEERING SCAFFOLD FABRICATION, 
EFFECTIVE DIFFUSION COEFFICIENT AND DYNAMIC CELL 
CULTURE*
 
 
Overview: This chapter discuses scaffolds fabrication procedures with different polymer 
concentrations, measuring oxygen diffusivity of scaffolds and screening them using their 
morphology and oxygen diffusivity, seeding cells on tubular and disk shaped scaffolds, 
culturing cell-seeded scaffolds in perfusion bioreactor, and analyzing the cultured cell 
seeded scaffold using confocal microscopy, hematoxylin and eosin staining, and Western 
blots.  
Summary 
Tubular and disk shaped poly (carbonate urethane) (PCU) scaffolds for in vitro tissue 
engineering of vascular grafts were fabricated by a solvent casting and particulate 
leaching method using NH4Cl as porogen. A better pore interconnectivity and oxygen 
diffusion coefficient were resulted in scaffolds fabricated using 15% PCU in N,N-
dimethylformamide (DMF). Human coronary artery smooth muscle cells (HCASMCs) 
were seeded in these scaffolds and cultured up to 28 days under static or under flow 
conditions in a perfusion bioreactor. For disk-shaped scaffolds, a better cell infiltration 
depth and distribution was observed in the flow condition than static culture controls 
whereas for cell seeded tubular scaffolds, higher number of cells were seeded and cells 
                                   
* A version of this chapter is submitted for publication and is currently under review. 
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infiltrate into the tubular scaffolds and, a uniform distribution of cells throughout the 
scaffold thickness was observed as shown by hematoxylin and eosin staining. Finally, 
Western blot data suggested an upregulation of ECM proteins such as elastin. The results 
demonstrate that scaffolds with low diffusivity were able to successfully integrate 
HCASMCs as a step toward to the development of tissue engineered vascular grafts.  
Keywords: Oxygen diffusivity, 3D scaffolds, perfusion bioreactor, tissue engineering 
3.1 Introduction 
Tissue engineering and regenerative medicine have emerged as promising methods for 
addressing the increasing demand of small-diameter replacements for diseased 
vasculature.1, 2 However, small-diameter arterial reconstructions (inner diameter <6 mm), 
are not available to date.3 Natural or synthetic polymeric scaffolds have been widely used 
in tissue engineering and regenerative medicine.4-6 The optimal scaffold structure is 
selected based upon a combination of mechanical and physical factors, one of which is 
the degree to which oxygen can diffuse though the scaffolds.7, 8 The ability of scaffold to 
support cell growth throughout its thickness is affected by the scaffold oxygen diffusivity. 
In vitro tissue maturation and immediately after surgical implantation until adequate 
vascularisation has occurred, cells seeded into the scaffold mostly depend on the process 
of diffusion for oxygenation.9-11 Therefore, the measurement of oxygen diffusivity in 
scaffolds is a logical method for comparing the ability of scaffolds to support cell 
viability, migration and infiltration within the scaffold.12, 13  
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Tissue-engineered small diameter vascular grafts have the ability to sense hemodynamic 
loading during dynamic culture, speciality when the culture media flows through the 
lumen, and respond through mechanical and biological responses.2, 14, 15 Mechanical 
stimulation of cells seeded in vascular tissue engineering scaffold promotes the 
circumferential orientation of cells as well as the deposition of extracellular matrix. 
Perfusion bioreactors also mimic the physiological conditions of coronary arteries and 
can impose mechanical stimulation to cells and the hemodynamic loading during cultures 
to engineer small diameter vascular grafts.16, 17 
In the present study, scaffolds with different morphology were fabricated by varying the 
PCU concentration, and were screened based on the measured effective oxygen 
diffusivity. Based on morphology and oxygen diffusion coefficient, the best polymer 
concentration for fabricating scaffolds was chosen. In view of developing small diameter 
vascular grafts in vitro, HCASMCs were seeded on PCU scaffolds with disk and tubular 
shapes. The cell seeded scaffolds were cultured in a perfusion bioreactor under 
physiological flow conditions for several days. The advantage of dynamic culture in 
regulating cell proliferation and distribution was evaluated by comparing the results with 
static culture controls.   
3.2 Materials and Methods 
3.2.1 Fabrication of PCU scaffolds 
3D scaffolds were fabricated by a solvent casting and particulate leaching method as 
shown in Figure 3.1.18 Ground and sieved NH4Cl porogens (180-220 µm) were packed 
into a tubular glass mold (6 mm outer diameter, 5 mm inner diameter and 8 cm height) 
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using a pressure differential created from an air supply line (550 kPa) from the top 
pushing and (0.014 kPa) suction applied from the bottom of the assembly. A medical 
grade poly(carbonate urethane) (PCU) (Bionate® 55D) was obtained from DSM 
Biomedical (Berkeley, CA). Different concentration of the PCU solution (15, 20, 25 and 
30 wt%, dissolved in N,N-dimethylformamide) was subsequently poured over the 
porogen bed and pressurized to infiltrate the porogen bed.  Following this, the scaffolds 
were removed from the assembly and the solvent was allowed to evaporate in a fume 
hood. Finally, NH4Cl porogens were leached out using deionized water and, the scaffolds 
were sectioned into 1.5 mm height disks using a microtome. This height (or thickness) of 
the scaffolds was chosen to mimic the thicknesses of many soft tissues that are the subject 
of tissue engineering.  
Tubular scaffolds were made in the same apparatus but with different assembly; a 
cylindrical stainless steel rod (4 mm diameter) was placed at the center of the tubular 
glass mold and the NH4Cl porogens were packed in the space between the rod and the 
glass mold. A polymer solution (15 wt %) was poured and pressurised to infiltrate into the 
porogens bed; the mold is then removed from the assembly and placed in the fume hood 
for 3 days for the solvent to evaporate completely. Finally, the scaffolds were removed 
from the mold and the NH4Cl porogens were leached using deionized water (DI) and the 
rod was removed from the center of the scaffold, the scaffolds were sectioned into 120 
mm length using a microtome.   
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Figure 3.1: Schematic diagram of the assembled, solvent casting and particulate 
leaching, scaffold fabrication method and scaffolds fabricated from PCU. 
3.2.2 Measuring dissolved oxygen and diffusion coefficient    
The diffusion apparatus, built by the University Machine Shop, consisted of two 100 ml 
chambers separated by the test scaffold, which was secured between the glass chambers 
with stainless steel insert and rubber gasket o-rings (Figure 3.2). The opening between the 
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two chambers had an area of 19.625 cm2. Each chamber was filled with 100 ml DI water. 
The DI water in the donor chamber was saturated with ambient air; the DI water in the 
receiver chamber was purged of dissolved oxygen by saturating with 100% nitrogen. To 
approximate a well-mixed system, the solutions in each chamber were stirred throughout 
the experiments. The oxygen concentration in the donor chamber was kept constant by a 
continuous supply of ambient air. Both chambers were maintained at 37oC by an external 
water bath. Fibre optic oxygen sensor model NeoFox (Ocean Optics, Dunedin, FL) 
equipped with NeoFox software was used to measure dissolved oxygen. The oxygen 
sensor was placed in the receiving chamber and measured dissolved oxygen every 10 
seconds.  
 
Figure 3.2: Schematic diagram of the diffusion cell apparatus 
The flux of oxygen in the test scaffold can be calculated by performing a shell material 
balance on the scaffold in one dimension leading to,  
Accumulation = Input  Output + Production  Consumption− −  
in outs s sz z z
CV J A J A PV GV
t +∆
∂
= − + −
∂
            (1) 
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Where: 
Vs is volume of the fraction of scaffolds where the mass balance was calculated  
A is the cross sectional area of the scaffold 
inJ is the inlet flux crossing the area 
outJ is the outlet flux crossing the area 
 Z is the thickness of the scaffold, and 
P and G are production and consumption of oxygen per volume of scaffold respectively.  
At a steady state and with no consumption and production of oxygen in the scaffold, the 
above equation reduces to diffusion in the z direction. 
2
2 0eff
d CD
dz
=                 (2) 
Where effD  is the effective diffusivity. 
With both donor and receiver chambers well-mixed, the boundary conditions for (2) are 
the concentration of oxygen in the donor and receiver chambers. Thus,  
BC1: (0)      BC2 : ( ) ( )D RC C C Z C t= =  
Where DC  and RC are the concentration of oxygen in the donor chamber and receiver 
chamber respectively.  
The solution of the diffusion equation (2) will be,  
( )R D
D
C t CC x C
Z
− = + 
 
               (3) 
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Therefore, the flux in the scaffold will be,  
( )R D
eff eff
C t CCJ D D
z Z
−∂  = − = −  ∂  
                        (4) 
Since the mass balance in the receiving chamber will be unsteady state with no 
consumption and production, equation (1) reduces to. 
( )R
R
C tV JA
t
∂
=
∂
                                  (5) 
Where, RV  is the volume of the receiver chamber.  Substituting the flux from (3) and 
solving for the receiver chamber oxygen concentration gives: 
0ln  
( )
R D
eff
R D
C C D t
C t C
ϕ
 −
= − 
                  (6) 
where = RV Z
A
ϕ  
Oxygen concentration was measured as a function of time for each scaffold and plotted as 
a function of time. Using equation (4), the linear slope of the best fit line (as calculated by 
the least-squares method using Sigma Plot Version 10) gives the effective diffusivity, 
effD , of the each scaffolds. 
3.2.3 Cell culture in perfusion bioreactor   
Primary human coronary artery smooth muscle cells (HCASMCs) and smooth muscle 
growth media (SmGM®-2 BulletKit) were purchased from Lonza Walkersville Inc. 
(Walkersville, MD, USA). Cells were cultured according to supplier’s instructions in 
SmGM®-2, supplemented with 100 units/ml penicillin G sodium, and 100 µg/ml 
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streptomycin sulphate (Invitrogen, Burlington, ON, Canada). All cultures were 
maintained in a humidified incubator at 37ºC containing 5% CO2. HCASMCs were 
passaged every 7 days at a split ratio of 1:3 and used between passages 4 to 7. Disk-
shaped scaffolds were affixed to glass coverslips using silicone grease, sterilized with 
70% ethanol for 30 min and allowed to dry under germicidal UV light in tissue culture 
hood for 30 min. After soaking the scaffolds in Hank's Buffered Salt Solution (HBSS, 
Invitrogen, Burlington, ON, Canada), all scaffolds were coated with fibronectin (10 
µg/cm2; Santa Cruz, CA, USA). Cells were seeded into the interstices of fibronectin-
coated PCU scaffolds at an initial cell density of ~3×104 cells/scaffold.  After HCASMCs 
attached to the scaffold for two days in static culture, the cell seeded scaffolds were 
transferred to a perfusion bioreactor and cultured for 4 and 7 days. The culture medium 
was purged through the porous cell seeded scaffold at a flow rate of 40 ml/min. A parallel 
static HCASMCs cultures were carried out as controls for 4 days and 7 days where 
culture medium was changed every other day.  
A similar sterilization and preconditioning steps were used for tubular scaffolds but cells 
were seeded into the lumen of fibronectin-coated PCU tubular scaffolds at an initial cell 
density of ~1×106 cells/scaffold. HCASMCs were statically cultured in a slowly rotating 
glass tube for two days to achieve uniform seeding and attachment to the scaffold. The 
cell-seeded scaffolds were then transferred to a perfusion bioreactor and cultured for a 
further 4 days, 7 days and 14 days at a medium flow rate of 40 ml/min. The calculated 
wall shear stress was (τw= 1.74 dyns/cm2) and it is below the physiological maximum 
shear stress in coronary arteries.10  
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3.2.4 Fluorescence staining and laser scanning confocal microscopy 
HCASMCs were fixed at room temperature for 1h with 4% (w/v) paraformaldehyde 
(EMD Chemicals Inc.) and the tubular scaffolds then sectioned circumferentially using 
microtome and axially using surgical blades.  The cells were permeabilized for 10 min in 
cation-free phosphate buffered saline (PBS) containing 0.1% (v/v) Triton X-100. Cells 
were incubated for 1h at room temperature in 1% BSA/PBS containing AlexaTM Fluor 
488-conjugated phalloidin (1:50 dilution), followed by three washes with PBS. DAPI 
(300nM in PBS; Invitrogen, Burlington, ON, Canada) was used to label nuclei. Samples 
were mounted on slides in SHUR/MountTM (TBS®, NC, USA) and analyzed with a Zeiss 
LSM 410 confocal microscope (Zeiss, Canada) equipped with an argon/neon as well as a 
UV laser. 
3.2.5 Histologocal analysis using haematoxylin and eosin staining  
HCASMCs cultured on PCU scaffolds were washed twice by ice cold PBS and embedded 
in optimum cutting temperature (OCT) media (Tissue-Tek, VWR, Canada) in dry ice bath 
and frozen to -80oC for 12h. The frozen blocks were transferred to cryotome crystat (-
20oC) and allowed the temperature of the frozen blocks to equilibrate to that of the 
cryotome crystat.  50μm thickness samples were sectioned using cryotome and placed on 
glass slides and the slides were heated to 30oC allowing the Tissue-Tek to melt. The 
sectioned samples were carefully washed twice with PBS and fixed using 4% (w/v) 
paraformaldehyde for 5 min, followed by two washes with DI water and then stained first 
with hematoxylin and then with eosin (Sigma-Aldrich) with washes with DI water in the 
intermediate and final stages of staining.  
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3.2.6 Protein extraction and Western blot analysis 
Following prescribed culture times, constructs were washed with ice cold PBS and 
proteins were extracted using lyses buffer. The lysate was collected and spun in a 
centrifuge and the supernatants were collected.  The amount of total protein was 
quantified using BSA protein assay kit (Thermo Scientific, ON, Canada). 50 µg protein 
samples were separated by 10% SDS-PAGE and subsequently transferred at 90 V for 1 
hour at 4ºC to nitrocellulose membrane in a Tris-glycine buffer. Coomassie blue was used 
to stain the total protein in gel. In addition the transfer efficiency and homogeneous 
loading was assessed by Ponceau red stain. Nitrocellulose membranes were blocked with 
5% nonfat dry milk in PBS and incubated overnight at 4ºC with primary antibodies 
(monoclonal mouse anti-elastin at 1:200; anti-SM-α-actin and anti-GAPDH at 1:2000). 
The blots were then labeled with Alexa 680- and IRDye 800-conjugated secondary 
antibody (Invitrogen, Burlington, ON, Canada), and labeled proteins were visualized by 
the Bio-Rad system (Bio-Rad Laboratories, Mississauga, Canada).  
3.2.7 Statistical analysis  
The results for the dissolved oxygen study and effective diffusion study were analyzed by 
Student’s t-test. For all analyses, significance was assigned for p < 0.05. 
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3.3 Results  
3.3.1 Scaffold fabrication  
Tissue engineering scaffolds are required to have high porosity and pore 
interconnectivity, and high surface area to volume ratio for cellular infiltration, matrix 
remodelling, and nutrient transport to take place. In such scaffolds, cell seeding density 
and distribution increases with pore interconnectivity. We therefore sought to examine the 
effect of polymer concentration on porosity and interconnectivity of the scaffolds. 
Different polymer concentrations (15, 20, 25, and 30 wt %, PCU dissolved in N,N-
dimethylformamide) were used to make PCU scaffold and the resulting scaffold were 
characterized using SEM. The strut thickness increased and pore interconnectivity 
decreased as the amount of polymer increased in the polymeric solution as shown in 
Figure 3.3. Scaffolds with lower polymer concentration were tried to fabricate but the 
structures were fragile and difficult to handle. Therefore, 15 wt% polymer concentration 
in DMF has been selected for further cell studies.  
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Figure 3.3: SEM photomicrographs of PCU scaffolds fabricated from different 
polymer concentrations.  15 wt % (A and B), 20 % wt (C and D) 25 % wt (E and F), 
and 30 % wt (G and H) PCU concentration. Scale bars are 250μm for A, C, E G and 
10μm for B, D, F and H. 
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3.3.2 Effective oxygen diffusion coefficient in scaffolds  
Fick's first law of diffusion on the passive transport of dissolved oxygen through the 
thickness of clinically relevant scaffolds within an enclosed, well-mixed system was 
applied to measure effective diffusion coefficient. Effective diffusivity measures the 
resistance or the ability of a material to allow the passage of oxygen through it and Figure 
3.4 show how the effective diffusivity can be calculated using the measured values of 
dissolved oxygen in the receiver chamber by means of equation (6). Scaffolds fabricated 
from 15 wt% polymer concentrations showed lower effective diffusivity than the other 
concentrations (Figure 3.5). As the concentration of polymer used to making scaffold 
increases the effective diffusivity increases as shown in the Figure 3.5. The higher 
effective diffusivity in the scaffold will have higher cell retention and easier to supply 
oxygen to the cells seeded on the scaffold. Therefore, scaffolds fabricated from 15 wt % 
polymer concentration will have less resistance to oxygen supply to the seeded cells. This 
result in combination with the SEM result suggests that 15% PCU concentration to be 
suitable for cell culture and have been chosen for further cell culture studies.    
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Figure 3.4: A) Oxygen concentration detected in the receiver chamber as a function 
of time. Data used to calculate the effective oxygen diffusivity, effD B) for 15% PCU, 
C) 20% PCU, D) 25% PCU and E) 30% PCU. 
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Figure 3.5: Effective oxygen diffusivity (cm2/s) in 3D scaffolds fabricated from 
different PCU concentrations. Data are mean ±SD for 3 independent experiments. 
NS means not significant.  
3.3.3 Fluorescence staining and confocal microscopy 
HCASMC-seeded disk-shaped scaffolds with 1mm thickness were cultured in a perfusion 
bioreactor where the culture media flows through the scaffold. After 4 days of culture, the 
cell-seeded scaffolds were imaged. A diffused red autofluorescence was observed due to 
the PCU scaffolds helped to demonstrate that HCASMCs were penetrating into the 
scaffold, but this did not affect the imaging process. HCASMCs were uniformly 
distributed on the scaffold as shown in Figure 3.6. Comparing with the static culture 
control, the cell density of the dynamic culture appeared to be similar. However, taking a 
series of confocal images with 10 μm apart from the top of the scaffold to the point where 
there are no more HCASMCs encountered, penetration depth to the scaffolds in dynamic 
cultures was considerably higher than the static control cultures (230 μm vs.  120 μm) 
suggesting that dynamic cultures improve cell penetration depths to the scaffolds whereas 
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this is not totally unexpected it does underscore the role of dynamic cultures to enhance 
cell distribution and penetration depth.   
 
Figure 3.6: Confocal microscopy images of HCASMCs cultured on disk shape PCU 
scaffold in static (A-D) and dynamic (E-H) culture conditions. The top of the 
scaffolds are shown in A and E whereas the bottom side are B and F, and the 
orthogonal projections are C and G.  Scale bar for all the images is 200μm. 
In addition, HCASMCs seeded on tubular scaffolds were cultured for 4 days, 7 days, 14 
days, and 28 days in a perfusion bioreactor where the culture medium flows through the 
lumen of the tubular scaffolds.  Cells were seeded from the lumen direction and cultured 
in slowly rotating tubular glass for two days; this seeding approach with the high seeding 
density helped to uniformly distribute throughout the scaffold from the lumen direction. 
Figure 3.7 shows the confocal images of HCASMCs taken from different areas of the 
scaffold. The cytoskeleton of the cells cultured in dynamic environment in the confocal 
images are somewhat diffused in their quality. This is likely due to the topography effect 
since the static cultures were conducted using porous disks whereas the dynamic cultures 
were done using tubular scaffolds. In both cases, however, the high density of cells is 
evident.  
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Figure 3.7: Confocal microscopy images of HCASMCs cultured on tubular PCU 
scaffolds in static (A, C, E and G) and dynamic (B, D, F and H) culture conditions 
for 4 days (A&B) 7days (C&D) 14 days (E& F) and 28 days (G&H).  Scale bar for 
A,B,G and H is 200μm and for C,D,E and F is 100μm. 
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3.3.4 Cross-sectional histological staining  
Homogeneous distribution of HCASMCs in the tubular PCU scaffolds was confirmed by 
means of histological staining with H & E as shown in Figure 3.8 which is consistent with 
confocal images of the fluorescent staining. The high magnification of the H & E staining 
shows a uniformly distributed of HCASMCs throughout the tubular PCU scaffold (B, D 
and E). A high HCASMCs staining with the number of culture days was an indication of 
cell proliferation.        
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Figure 3.8: H&E staining of cross sections of HCASMCs seeded tubular PCU 
scaffolds cultured under dynamic condition for 7 days (B and C), 14 days (E and F) 
and 28 days (G and H). Bare scaffold was stained and imaged as a control (A and B). 
Scale bar for A, C, E and G is 0.2mm and for B, D, F and H is 0.1mm.  
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3.3.5 Western blot analysis 
The total amount of protein from cell lysates cultured in dynamic and static conditions for 
14 and 28 days was quantified using BSA protein assay. An equal amount of protein 
(50μg) in each lane of the PAGE was run and the gel was stained using coomassie blue, 
and subsequently imaged by Bio-RAD camera (Molecular imager Chemi DocTM). The 
intensity of the protein bands in each lane is indicative of the relative amounts of protein 
present.  In the region of 50 kda to 100 kda, most proteins were upregulated in dynamic 
cultures than in static culture controls as shown in Figure 3.9A. Therefore, further 
staining for elastin (molecular weight ~66kda) and Smooth muscle α-actin (molecular 
weight ~42kda) showed an upregulation in dynamic cultures than in static cultures as 
shown in Figure 3.9 B. indicating a more synthetic  phenotype of HCASMCs in dynamic 
than static cultures.  However, a more controlled and detailed experiments need be done 
in order to get a better conclusive result.  
 
Figure 3.9: Western blots of 14 days and 28 day cultures in static and dynamic 
conditions coomassie blue staining and antibody staining of elastin, SM-α-actin and 
GAPDH for 14 days culture.  
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3.4 Discussion  
The effective diffusivity measures the ability of a scaffold to allow the transport of 
oxygen through it. In this study it is shown that 15 wt% polymer concentration has a 
higher diffusion coefficient allowing higher amount of oxygen to be transported; these 
results in higher cell viability, penetration depth into the scaffolds, and proliferation.  
These findings suggest at least a partial dependence of oxygen transport on the polymer 
concentration, porosity, and/or tortuosity of the scaffold. The tortuosity of the scaffold 
were not directly measured in this study but instead incorporated into the effective 
diffusivity variable.19  The SEM results also suggested 15 wt% polymer concentration 
scaffolds resulted in higher pore interconnectivity. Whereas most studies on oxygen 
diffusion through tissue engineering scaffolds focused on numerical analysis 
approaches20-23, there are few studies related to the current work for experimentally 
determining oxygen diffusivity. For example, Valentin et al24 measured oxygen 
diffusivity of small intestine submucosa, urinary bladder submucosa, and Dacron®. Not 
unexpectedly, their data indicated that each scaffold has unique oxygen diffusivity values 
ranging from 2.4x10-6 cm2/s to 6.6x10-6 cm2/s, and these values were dependent on the 
scaffold's ultrastructure. Dacron® had oxygen diffusivity which was one order magnitude 
higher than the ECM scaffolds presumably due to the woven nature of it.  In another 
related study, Androjna et al25 measured the oxygen diffusivity of intestine submucosa, 
human dermis (Alloderm®), and canine fascia lata and reported the effective diffusion 
coefficients of all 3 ECM-based scaffolds to be to be in the order of 7x10-6 cm2/s to 4x10-
5 cm2/s with the intestine submucosa tended to have the lowest oxygen. The differences in 
the reported ranges are likely due to varying matrix structure porosity and tortuosity that 
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is inherent in these tissues. In view of these cited studies, the oxygen diffusivity in all 
PCU scaffolds (Figure 3.5) was comparable to natural ECM scaffolds. More importantly, 
the oxygen diffusivity for 15wt% was better than ECM scaffolds but lower than Dacron®. 
From this comparison it is possible to deduce that our scaffolds transports oxygen higher 
than biological scaffolds but lower than synthetic scaffold Dacron®. To the best of our 
knowledge, this study is the first to show oxygen diffusivity in PCU scaffolds as a 
function of polymer concentration during the fabrication process. 
HCASMCs penetration depth increased in dynamic cultures than the static culture 
controls. This signifies higher cell population in the 3D scaffold, a finding that is also 
supported by prior studies as Chan and Chong showed that perfusion systems increased 
the oxygen profile in the scaffold, which in turn, increased the cell number with uniform 
cell density.26  In addition, HCASMCs penetrated throughout the thickness of the tubular 
scaffold as shown by the H&E staining. These results are consistent with literature reports 
for other types of scaffolds. For instance, using H&E staining, Poot and coworkers 
showed that VSMCs seeded into porous, tubular, flexible, and elastic poly(trimethylene 
carbonate) scaffolds and cultured under perfusion had higher cell numbers. Interestingly 
cell number peaked at day 7 and then decreased at day 14.3, 27 The mechanical properties 
of the scaffolds also increased with culture time suggesting possible matrix deposition.  
Although direct comparison with the above cited work cannot be done as we have not 
specifically stained for ECM components in the histology study, reasonable inferences 
can be drawn from the Western blot data (Figure 3.9B) that HCASMCs started expressing 
elastin, one of the most important ECM component for vascular tissues. Previous studies 
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from our laboratory also demonstrated the biosynthesis of both elastin and collagen by 
HCASMC seeded to PCU scaffolds.28, 29       
Notwithstanding the above, however, endothelialisation of the luminal surface of the 
engineered vascular tissues is an additional requirement that must be satisfied from a 
practical standpoint. Previously, the co-culturing of human coronary artery endothelial 
cells and HCASMCs on scaffolds by using Matrigel coating was reported.2 Matrigel-
coated layer not only was a structural mimic for the basement membrane (internal elastic 
lamina), but also functioned to help chemically anchor other components, such as 
laminins, collagen IV, nidogens (entactin) and heparan sulfate proteoglycan (perlecan).30 
This approach could also be used for endothelialisation of the constructs described in the 
present work. Furthermore, co-culture of endothelial cells and HCASMCs play a role in 
the alignment of HCASMCs along the direction of flow.31 Moreover, co-culturing plays a 
significant role in the phenotype regulation of HCASMCs. Our group showed evidences 
that contact of HCASMCs and endothelial cells is required for the regulating smooth 
muscle cell differentiation.32 .   
3.5 Conclusions  
A new way of screening scaffolds with effective diffusivity led to an observation that 15 
wt% PCU scaffold could be used to engineer vascular grafts with good structures and 
pore interconnectivity. Porous tubular and disk-shaped PCU scaffolds were seeded with 
HCASMCs and subsequently cultured up to 28 days under flow conditions in a bioreactor 
and static conditions. Both confocal and histological studies showed that dynamic culture 
conditions significantly improved HCASMC penetration and uniform distribution 
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throughout the scaffold as compared with static culture controls. The results of this study 
indicated that a potentially useful tissue engineered vascular grafts can be fabricated by 
dynamic culturing of human HCASMCs seeded in porous tubular PCU scaffolds. 
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CHAPTER 
         4       
  
4 EXPERIMENTAL AND MODELING STUDIES OF OXYGEN 
TENSION IN VASCULAR TISSUE ENGINEERING WITH AND 
WITHOUT AN OXYGEN CARRIER*
 
 
Overview: This chapter provides the use of perfluorodecalin (PFD) as oxygen carrier in 
vascular tissue engineering. In doing so the amount of oxygen dissolved in PFD emulsion 
was measured and the toxicity of PFD to vascular smooth muscle cells seeded on 3D 
scaffold were examined and finally a mathematical model was developed for oxygen 
profile in the lumen and 3D scaffold constructs.       
Summary 
The technology of vascular tissue engineering holds promise in the design of responsive 
living conduits with properties similar to those of the native tissue. This approach, 
however, constitutes an important engineering challenge because of the difficulty to grow 
cells in high density, due to mass transfer limitations (delivery of nutrients and removal of 
metabolic waste products). The major mass transfer challenge in tissue engineering arises 
from the inability to deliver sufficient oxygen because of its low solubility and diffusivity 
in culture media. In this work the utility of perfluorodecalin (PFD) as an oxygen carrier to 
enhance oxygen delivery for the growth of human coronary artery smooth muscle cells 
                                   
* A version of this chapter is published: Seifu, D; Mequanint, K. (2011) Experimental and Modeling 
Studies of Oxygen Tension in Vascular Tissue Engineering. Journal of Biomaterials and Tissue Engineering 
1, 49-59 
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(HCASMCs) seeded at high density on porous 3D polyurethane (PCU) scaffolds is 
described. Furthermore, the diffusive and convective lumen and ablumen oxygen 
distribution in engineered vascular tissue constructs is modeled. Both experimental and 
modeling data demonstrated that oxygen tension on 3D scaffolds was improved by using 
PFD as an oxygen carrier. Dissolved oxygen in the culture media with PFD was 
significantly higher than the other fluids tested (p = 0.0017). Furthermore, HCASMC 
number was significantly higher in the presence of PFD than in control scaffolds. Taken 
together, these data suggest that PFD could be used as oxygen delivery vehicle in 
vascular tissue engineering strategies. 
Keywords 
Vascular tissue engineering, oxygen transport, perfluorodecalin  
4.1 Introduction 
The strategy of in vitro vascular tissue fabrication is conceptually simple and appealing 
yet it has proven to be a challenging engineering endeavour. Despite rapid advances made 
in this field, success is still limited. 1 Compared with native tissues, one of the major 
unsolved challenges in engineering three-dimensional (3D) tissues is the lack of 
vascularization resulting in poor oxygen mass transfer.  Oxygen can be supplied to 
vascular cells seeded into a tubular scaffold by radial diffusion from the lumen such that 
the oxygen concentration decreases from the lumen and the outer limit of the construct. 
Oxygen diffusion within the scaffold can be enhanced by increasing the overall diffusion 
coefficient, decreasing the diffusion distance, and increasing convective transport. Since 
tissue engineering is carried out in a bioreactor, hydrodynamic conditions can affect in 
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vitro tissue formation in at least two ways:2 i) by direct effects of hydrodynamic forces on 
cell morphology and function, and ii) by indirect flow-induced changes in mass transfer 
of nutrients and metabolites. In static flask bioreactors, tissues are fixed in place and 
cultured without hydrodynamic shear at tissue surfaces while relying on diffusional 
oxygen transport for cell survival. In spinner flask bioreactors, tissues are fixed in place 
and exposed to the steady turbulent flow of medium, which enhances oxygen mass 
transfer but the level of mixing intensity required often surpasses the shear tolerance of 
the cells.3 In a rotating-wall bioreactor, tissues are dynamically suspended in a laminar, 
rotational flow field, and mass transfer is enhanced by laminar convection due to 
construct settling. However, cell-seeded scaffolds often undergo repeated wall collisions 
in rotating bioreactors, which disrupted tissue formation.4 Further, rotating-wall 
bioreactor provided oxygen transfer only to the outer 100μm thick layer.5 Due to a tubular 
scaffold requirement, none of the aforementioned bioreactor designs are suitable for 
fabricating vascular tissues.   
In order to improve oxygen transfer, oxygen generating scaffolds and perfluorocarbon 
compounds as oxygen carriers has been proposed. For example, in cardiac and tracheal 
tissue engineering, perfluorocarbons have been shown to improve construct oxygenation 
without the above-mentioned adverse effects to the growing constructs.6-8  In this regard, 
a steady state model for oxygen distribution in cardiac tissue constructs with parallel 
channel array mimicking the in vivo capillary tissue bed and PFC compound oxygen 
carrier was developed by Vunjak-Novakovic and co-workers.6 Despite this interesting 
approach, the application of this model is limited to tissues such as cardiac and cartilage 
because of the impracticality to create channel arrays within the cross section of vascular 
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scaffolds. Further, at a wall-to-wall channel spacing of ~370μm, supply of sufficient 
oxygen to seeded cardiomyocytes was not achieved. In vascular tissue engineering, 
culture medium is pulsed and allowed to flow through the lumen which is anticipated to 
cause transmural oxygen diffusion through the construct wall. However, in previous 
studies the oxygen tension in the scaffold cross-section was neither predicted nor 
measured.9, 10 Another reported approach to fabricate vascular tissues is a radial flow 
culture system where oxygen dissolved in the culture medium entered into the lumen at 
one end and forced out through the scaffold wall as transmural flow (by sealing the other 
end of the lumen).11 However, the oxygen distribution in this study was not reported.  In 
fact, it can be argued that bioreactors for vascular tissue engineering have been studied 
primarily for mechnotransduction rather than for oxygen transport studies.12, 13 Recently, 
Bjork and Tranquillo14 reported a novel approach by combining both transmural and axial 
flows to enhance oxygen transfer to rat vascular smooth muscle cells seeded into 3D 
fibrin gel. Their data, however, suggest detrimental effects due to the lumenal pressure 
needed to force transmural flow exceeding the burst pressure of the construct. 
To overcome the aforementioned drawbacks while still at the same time delivering 
sufficient oxygen, we propose a combined approach whereby perfluorodecalin-
supplemented culture medium flows from both the lumen and ablumen sides of the 
construct. In this manuscript we first present experimental evidences on the feasibility of 
perfluorodecalin as an oxygen carrier. This is followed by a mathematical model for the 
lumen and the tissue space oxygen distribution with perfluorodecalin as oxygen carrier in 
a tubular scaffold both in static and in convective transport modes.  
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4.2 Methods 
4.2.1 Fabrication of 3D scaffolds 
A medical grade poly(carbonate urethane) (PCU) (Bionate® 55D), kindly donated by the 
Polymer Technology Group (Berkeley, CA), was used to fabricate 3D scaffolds by a 
solvent casting and particulate leaching method as previously described.15 Briefly, ground 
and sieved NH4Cl porogens (180-250 µm) were packed into a cylindrical infiltration 
chamber, the polymer solution (15 wt% PCU dissolved in N,N-dimethylformamide) was 
subsequently poured over the porogen bed and pressurized to infiltrate the porogen bed.  
Following this, the scaffolds were removed from the assembly and the solvent was 
allowed to evaporate in a fume hood. Finally, NH4Cl porogens were leached out using de-
ionized water to obtain porous vascular scaffolds (Figure 4. 1A).  
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Figure 4.1: SEM and digital image of PCU scaffold (A), tubular construct of porous 
cell-seeded scaffold and mesh alignment of the model (B), perfusion bioreactor 
digital image and schematic flow diagram including the setup (C) 
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4.2.2 Dissolved oxygen measurements  
Fibre optic oxygen probe model NeoFox (Ocean Optics, Dunedin, FL) equipped with 
NeoFox software was used to measure dissolved oxygen. 2% perfluorodecalin (PFD) 
(95% mixture of cis and trans; Sigma-Aldrich) was emulsified in the presence of smooth 
muscle culture medium and continuously stirred at 37°C while the assembly was left open 
to atmospheric air. A 300nm diameter oxygen probe was used to measure the dissolved 
oxygen and a two point calibration, where 20.9% of oxygen at standard temperature and 
pressure and 0% of oxygen in 100% nitrogen, was used.  
4.2.3 Cell culture on 3D scaffolds  
Primary human coronary artery smooth muscle cells (HCASMCs) and smooth muscle 
growth media (SmGM®-2 BulletKit) were purchased from Lonza Walkersville Inc 
(Walkersville, MD, USA). Cells were cultured according to supplier’s instructions in 
smooth muscle growth media (SmGM®-2 BulletKit), supplemented with 100 units/mL 
penicillin G sodium, and 100 µg/mL streptomycin sulphate (Invitrogen, Burlington, ON, 
Canada). All cultures were maintained in a humidified chamber at 37ºC containing 5% 
CO2. HCASMCs were passaged every 7 days at a split ratio of 1:3 and used between 
passages 4 to 7. Scaffolds were sterilized with 70% ethanol for 30 min and allowed to dry 
under UV light in tissue culture hood for 30 min. After socking the scaffolds in Hank's 
Buffered Salt Solution (HBSS, Invitrgen, Burlington, ON, Canada) all scaffolds were 
coated with fibronectin (10 µg/cm2; Santa Cruz, CA, USA). Cells were seeded onto 
fibronectin-coated PCU scaffolds at an initial cell density of ~3×105 cells/scaffold. 
HCASMCs were cultured for 7 days, 14 days, and 21 days. 
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4.2.4 Cytotoxicity assay and cell number quantification 
For colorimetric assays of the metabolic activity of viable cells, 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) (Invitrogen, Burlington, ON, Canada) was 
used to quantify cytotoxicity following 24 h culture. MTT salts are reduced to a water-
insoluble formazan salt only by metabolically active cells allowing the assay to detect 
viable cells exclusively. After it was solubilized, the formazan formed was quantified by 
a plate reader at 570 nm (maximum absorbance). Negative control experiments were 
carried out by adding MTT to 3D scaffolds and culture medium without cells.  For cell 
proliferation, cells were removed from the scaffolds according to our reported 
methodology16 following specified culture times and counted using a hemocytometer.  
4.2.5 Fluorescence staining and laser scanning confocal microscopy 
HCASMCs were fixed at room temperature for 1 h with 4% (w/v) paraformaldehyde 
(EMD Chemicals Inc.) and permeabilized for 10 min in cation free phosphate buffered 
saline (PBS) containing 0.1% (v/v) Triton X-100. Cells were incubated for 1 h at room 
temperature in 1% BSA/PBS containing Alexa Fluor 488-conjugated phalloidin (1:50 
dilution), followed by 3 washes with PBS. DAPI (300nM in PBS; Invitrogen, Burlington, 
ON, Canada) was used to label nuclei. Samples were mounted on slides in 
SHUR/MountTM (TBS®, NC, USA) and analyzed with a Zeiss LSM 410 confocal 
microscope (Zeiss, Canada) equipped with an argon/neon as well as a UV laser. 
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4.2.6 Mathematical model for lumen oxygen profile 
A cylindrical coordinate as shown in Figure 4.1B is used to model oxygen transfer in cell 
seeded vascular scaffolds. A steady state oxygen balance in the scaffold lumen can be 
described by the conservation equation:17  
[ ]
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Where VZ is the culture medium velocity, L is the PFD volume fraction, Md is the oxygen 
dissociation constant of PFD, Z is the axial direction, r is the radial direction, effD  is the 
effective oxygen diffusion constant and C is the oxygen concentration. Equation (1) is 
subject to the following boundary and initial conditions:  
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The flow of the medium in the lumen is assumed to be fully developed and, the velocity 
profile is given by; 
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Where Vm is the average fluid velocity.  
In order to calculate the effective diffusion coefficient in equation (1), the following 
expression was used.18 
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Where p p
a a
C D
C D
γ = ; aD  is the aqueous phase diffusivity, aC dissolved oxygen in aqueous 
phase, pD  is diffusivity of PFD, and pC is dissolved oxygen in PFD.  
4.2.7 Mathematical model for cell-seeded scaffold oxygen profile 
A homogeneous cell-seeded scaffold, where culture medium flows both from the lumen 
and ablumen, was considered to model the oxygen profile in the tissue space.  The flux of 
oxygen from the lumen and ablumen were calculated with a consumption rate and with 
the effective diffusivity. A steady state differential equation for cell-seeded scaffold will 
have both the diffusion term and a consumption term (as represented by Michaelis-
Menten kinetics) in accordance with following equation:     
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m
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+
                                          (4) 
The boundary conditions for equation 4 are: 
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Dt  is the effective oxygen diffusivity in the tissue space and, the values were adopted 
from Riley et al 19 based on Monte-Carlo simulation. For cell volume fraction 
0.04<ϕ<0.95 in the scaffold: 
( )2 31 1 1.727 0.8177 0.09075t cell
o o
D D
D D
φ φ φ
 
= − − − + 
 
                                          (5)  
 
   89  
 
Where Dcell is the diffusivity of oxygen in cells, Do is the diffusivity of oxygen through 
the interstitial fluid space and ϕ is the volume fraction of cells.    
4.2.8 Model parameters  
The mathematical model equations presented above were implemented for the set of 
experimental conditions summarized in Table 4.1. In order to maintain the wall shear 
stress within the reported physiological values of normal coronary arteries 20 and to show 
the effect of flow rates, a flow rate of  15mL/min (τwall = 0.65 dynes/cm2), 23 mL/min 
(τwall  = 1 dynes/cm2),  and 40mL/min (τwall = 1.74 dynes/cm2) were used.  Average 
velocity was calculated based on cross-section area of the lumen. Maximum oxygen 
consumption (Vmax) for vascular smooth muscle cells was taken from literature.21 The 
volume fraction of the circulating PFD molecules was 2%. In addition to the lumen 
oxygen profile, the model was used to predict oxygen concentration profiles for vascular 
tissue constructs of clinically relevant thickness (1mm), flow rates, and cell density 
ranging from 106cell/mL to 5x106cell/mL. The cells were assumed to be uniformly 
distributed throughout the pores of the 3D scaffold. The corresponding volumetric 
maximum oxygen consumption rate (Vmax per unit volume) was calculated for the 
respective cell numbers. Culture medium at the inlet of the construct was assumed to be 
fully saturated with atmospheric oxygen with an oxygen partial pressure of 160 mmHg. 
The partial pressure of oxygen for culture medium supplemented with PFD was measured 
to be 220 mmHg using the reported value of oxygen solubility in PFD 37oC.22 
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4.2.9 Numerical solutions 
The solutions for the model equations were obtained using the PDE toolbox built in 
MatLab R2009a utilizing finite element model. In order to use the toolbox, the boundary 
conditions were modified as follows.  
• ( )e walln D C J∇ =
   (Neumann condition). Since the generalized Neumann condition 
in the PDE toolbox software is ( )en D C∇
 + qC = g, and C depends on r in this 
problem, this boundary condition was expressed as ( ) ( )e walln D C J r∇ =
    
• C = 220 mmHg at the left end of the cylinder (Dirichlet condition).  
• The cylinder axis at r = 0 is not a boundary in the original problem but in 2D 
treatment, due to symmetry, ( ) 0en D C∇ =
 .  
Solving equations (1) and  (4) took up to 1933 successful steps, zero failed attempts, 4053 
evaluated functions, 511 LU decomposition, 4053 solutions of linear systems with 
computation times ranging from 4 to 7 min. 
 
4.2.10 Statistical analysis  
The results for the dissolved oxygen study were analyzed by analysis of variance 
(ANOVA). Student’s t-test was used to analyze the cytotoxicity of PCU scaffold and 
proliferation of HCASMC as a function of culture time. For all analyses, significance was 
assigned for p < 0.05. 
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4.3 Results and discussion 
4.3.1 The effect of PFD on dissolved oxygen in HCASMCs culture medium, cell 
spreading and cell viability.   
In this work the feasibility of PFD to enhance oxygen delivery to vascular smooth muscle 
cells seeded into 3D scaffolds was investigated. The rationale for choosing PFD was 
twofold. Firstly, while dissolving high level of oxygen (ca. 42.3 ml per 100 ml of O2), it is 
reported that PFD has longer tissue retention time which holds promise for a clinical 
application compared with the most widely used perflubron 23. Secondly, unlike 
Oxygent™ whose primary content is perflubron, PFD is not investigated as oxygen 
carrier for tissue engineering applications. Because in vitro cell culture data using PFD is 
not reported, it was first investigated if this molecule could be a candidate to enhance 
oxygen delivery in vascular tissue engineering. Figure 4.2 shows the measured dissolved 
oxygen concentration in PFD-supplemented HCASMC culture medium and other fluids 
at 37oC and atmospheric pressure. There was no statistical significance between DI water, 
PBS and HCASMC culture medium. The oxygen solubility values in these fluids were 
comparable to the calculated value using Henry's law.  However, in comparison to the 
variety of biological fluids tested, there was a highly significant difference when 2% PFD 
was added in HCASMC culture medium (p=0.0017). This data shows that by 
incorporating 2% PFD in culture media, there was a significant increase of dissolved 
oxygen at 37oC. Dissolved gases are transported by perfluorinated compounds due to 
increased solubility in accordance with Henry's Law. The increase is attributed due to the 
existence of loose, non-directional van der Waals interactions leading to low cohesive 
energy densities, which facilitates mutual solubilization of oxygen in the fluorine 
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compound that is bound to the surface of the emulsion.24 To evaluate the possible 
cytotoxic effect of 2% PFD on cultured HCASMC, cells were cultured on coverslips with 
and without PFD for up to 7 days. The phase-contrast microscopy images (2D cultures) 
and confocal microscopy images (3D scaffolds) presented in Figure 4.3 demonstrated that 
the morphology and spreading of cells were not affected by the presence of PFD. The 
MTT assay data presented in Figure 4.4 also affirmed that 2% PFD was not cytotoxic to 
HCASMCs. Although data is not available for vascular smooth muscle cells, 
perfluorocarbon emulsions even at low concentrations are in general considered to be 
cytotoxic and inhibitor to proliferation in cultured human fibroblast cells 25, 26. Figure 4.4, 
on the other hand, demonstrates excellent cell viability which could be due to the 
differences in the type of perfluorocarbon used in our study and in the above-cited 
studies. Based on the feasibility data presented herein, a fixed 2% PFD was used to 
investigate cell growth in 3D scaffolds and to predict oxygen tension in our mathematical 
model. 
 
Figure 4.2: Dissolved oxygen partial pressure in different fluids measured at 37 oC. 
Oxygen concentration was measured using fibre optic probe. Data are mean ± SD 
for experiments conducted in triplicate. * indicates statistical significance. 
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Figure 4.3: Phase contrast images of HCASMC, cultured without PFD 
supplemented medium (A, C and E) and with PFD (B, D and F) for 1 days, 2 days 
and 7 days. Confocal microscopy images of HCASMCs cultured on 3D scaffolds 
with PFD (H) and without PFD supplemented medium (G). 
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4.3.2 HCASMC proliferation when seeded to 3D scaffolds with 2% PFD-
supplemented medium.  
In order to rationalize the modeling approach and to examine the effect of 2% PFD in 
culture medium, HCASMC proliferation on 3D scaffolds was investigated.  The results 
presented in Figure 4.5 demonstrated that cell number significantly increased following 7 
days, 14 days and 21 days of culture with 2% PFD (p < 0.05).  Since equal numbers of 
cells were seeded on all scaffolds and that both scaffolds and PFD were not cytotoxic, the 
significant increase in cell numbers as a function of time indicates that an environment 
conducive for cell growth was established by providing sufficient oxygen tension as will 
be shown in the mathematical model in the next section.   
 
Figure 4.4: HCASMC viability using MTT assay on 3D PCU scaffold cultured with 
and without PFD supplemented medium. Data are mean ±SD for experiments 
conducted in triplicate. * indicates statistical significance 
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Figure 4.5: HCASMC proliferation on 3D scaffolds with and without PFD 
supplemented medium for 7 days (A) 14 days (B) and 21 Days (C). Data are 
mean±SD for experiments conducted in triplicate. * indicates statistical significance. 
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4.3.3 Numerical solution for oxygen profiles in static 3D cultures.  
Diffusion and convection are the two main mass transfer mechanisms in cell seeded 3D 
scaffolds. To establish a baseline, the oxygen profile in both the lumen and tissue space 
was first simulated for static cultures where the lumen is filled by a stagnant culture 
medium. Since cells are seeded only to the scaffolds, there is no lumen oxygen 
consumption in the model equation so the lumen oxygen profile represents this fact. 
Therefore, it is expected that the oxygen distribution within the lumen is governed only 
by diffusion. Due to symmetry, only half of the lumen was modeled and, a representative 
lumen oxygen profile is shown in Figure 4.6A, from which it can be inferred that the 
oxygen partial pressure decreased rapidly as we move from the two ends of the scaffold 
lumen to the centre along the axis of the scaffold. The oxygen flux from the lumen by 
diffusion will be consumed by cells in the scaffold. At a cell density of 2.5x106cells/mL 
which was used to obtain the data for Figure 4.6A, the oxygen profile at the midpoint of 
the scaffold lumenal length (Z = 0) reached zero.  Figure 4.6A also shows that at any 
cross section of the lumen the concentration of oxygen is minimum at the interface 
between the scaffold and culture media and maximum at the center which follows the flux 
as shown by the direction fields (indicated by a series of red arrows in the radial 
direction). To study the effect of cell density, the lumen-scaffold interface oxygen 
concentration was plotted (Figure 4.6B). The model indicates that from all cell densities 
shown, oxygen diffusion from the lumen was sufficient only for low cell seeding density. 
Above 1.5x106 cells/ml diffusion alone was not able to deliver oxygen for cell survival as 
indicated by the corresponding partial pressure that drops to zero. It is to be recognized 
that a minimum oxygen concentration above 20 mmHg must be maintained in the lumen 
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to avoid a necrotic environment in the tissue space.27, 28 In addition to the lumen oxygen 
profile, the tissue space oxygen profile with and without PFD supplement was modeled 
and, the results are presented in Figure 4.7. Without PFD, oxygen partial pressure 
dropped to below 20 mmHg at a scaffold depth of ≈ 0.15  mm (Figures 4.7 A &C). 
Despite the enhancement in the oxygen penetration depth into the tissue space to about 
0.4mm, the presence of 2% PFD does not appear to be sufficient to supply enough 
oxygen to seeded HCASMCs as shown by the rapid depletion of oxygen with increased 
scaffold thickness (Figures 4.7 B &C).  
Table 4.1: Model parameters used to predict oxygen concentration profiles in a 
vascular tissue constructs oxygenated with PFD supplemented culture medium. 
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Figure 4.6: Model prediction of oxygen profile in the lumen at static culture 
condition in 3D plot (A) and a plot of lumen-scaffold interface oxygen partial 
pressure for different cell densities (B). 
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Figure 4.7: Oxygen profile in the scaffold (tissue space) at static condition in 3D plot 
with and without PFD supplemented medium (B, C) and a plot of cross sectional 
oxygen partial pressure for different cell densities (C). 
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4.3.4 Numerical solution for oxygen profiles in 3D cultures with convection 
The second part of the modeling study was done to include convective mass transfer to 
the diffusion. We assumed that the medium flow to be fully developed laminar flow 
which is reasonable because many practical bioreactors including ours have long tubing 
often forming loops from the pulse generator to the tissue construct (Figure 4.1C). Due to 
symmetry, only half of the lumen was modeled and; the concentration of oxygen on the Z 
direction is maximum at the inlet and minimum at the exit (Figure 4. 8A&B). In addition 
to that, Figure 4.8B shows that at any cross section of the lumen, the concentration of 
oxygen is minimum at the interface between the scaffold and culture medium and 
maximum at the center in the direction of the flux. The model prediction shows that the 
best result for oxygen profile in the lumen with 2% PFD is obtained when the flow rate is 
40 ml/min and HCASMCs are seeded at a density of 2.5x106 cells/ml. Although it is 
possible to increase the flow rate to enhance oxygen transfer either for higher cell density 
than the one assumed herein in the scaffolds or for longer scaffolds than the one utilized 
in this model, it should be pointed out that this can be done at the detriment due to 
excessive wall shear stress. At a lumen radius of 3mm, the wall shear stresses calculated 
in this model varied from 0.65 dynes/cm2 (corresponding to 15 ml/min medium flow) to 
1.74 dynes/cm2 (corresponding to 40 ml/min medium flow) which are physiologically 
relevant.20   
To model the oxygen profile in the tissue space, a homogeneous cell-seeded scaffold 
where culture medium flows both from the lumen and ablumen was considered. The 
rationale for the ablumen flow was to mimic the vasa vasorum that supply oxygen to 
smooth muscle and fibroblast cells within the media and adventitia of arteries. The 
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bioreactor in our laboratory is also able to supply essential nutrient from the lumen and 
the ablumen. 
  
Figure 4.8: Oxygen profile in the lumen and in the scaffold at a flow condition. A 3D 
representation of the oxygen partial pressure in half of the lumen (A), a plot of 
lumen-scaffold interface oxygen partial pressure for different cell densities (B), a 3D  
plot of the oxygen partial pressure in scaffold (C) and a plot oxygen partial pressure 
across the cross section of the scaffold for different cell densities (D). 
The flux of oxygen from the lumen and ablumen was calculated with a Michaelis-Menten 
consumption rate and with effective diffusivity and was subsequently used as a boundary 
condition to solve the oxygen profile in the tissue space. The numerical solution of the 
PDE given in equation 1 plotted in Figures 4.8 C&D showed that the concentration of 
oxygen is maximum at the scaffold-lumen interface and minimum at the centerline of the 
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scaffold wall thickness. At concurrent lumen and ablumen flow rate of 40 ml/min, culture 
medium supplemented with 2% PFD provided the necessary oxygen for up to, 3.75x106 
cells/ml. Although the vascular smooth muscle cells density assumed in this study is 
relatively lower compared with the physiologic values,29 it is deemed to be an acceptable 
density for vascular tissue engineering. The plots in Figure 4.8D showed that the oxygen 
partial pressure continuously decreased as one moves from the lumen-scaffold interface 
(thickness = 0) to the scaffold centreline (thickness = 0.5). This was followed by a 
continuous upward swing towards the outer scaffold space, reaching a maximum at 
thickness = 1mm. The oxygen partial pressure values at thickness = 0 and at thickness = 
1mm are not the same because of the differences in the outer and inner radius of the tissue 
space used in the model. Since the total flux is fixed based on oxygen consumption, 
oxygen transfer from the ablumen is higher than the lumen due to increased radius (and 
hence surface area).   
One key design element in tissue engineering is maintaining adequate mass transfer while 
at the same time providing local conducive environment to the differentiated state of 
seeded cells. The mechanism of oxygen transport and consumption in cells is an 
important problem which has received considerable attention in recent years30-32. Hoare 
and coworkers33 reported a window of operation to engineer vascular constructs with 
sufficient oxygen delivery based on convection and diffusion from the lumen. Whereas 
their approach captured the practical aspect of cell density in the construct space and the 
wall shear stress (calculated based on the given critical flow rates), the model 
underestimates both the wall thickness (0.2mm used in the model vs. 0.5mm-1mm for 
typical coronary arteries) and the oxygen consumption of vascular smooth muscle cells. 
   103  
 
Specifically, the oxygen consumption data used in their model is an order magnitude 
lower than the oxygen demand of vascular smooth muscle cells.14, 21 Due to these 
underestimations, we believe that their prediction will fall short of the physiologic 
relevance in both the wall thickness of the vascular constructs and the oxygen 
consumption of vascular smooth muscle cells. Although the oxygen consumption rate 
data in the work of Bjork and Tranquillo14 is realistic for vascular smooth muscle cells, 
the pressure required  to deliver oxygen via transmural flow was detrimental to the 
growing tissue constructs thus limiting their efforts. In addition, the 0.2 mm wall 
thickness used is lower than typical coronary arteries. By combining a practical wall 
thickness (1 mm), experimentally determined oxygen consumption rate of vascular 
smooth muscle cells, and physiologic wall shear stress, the present study suggests that 
without oxygen carrier molecules, fabrication of tissue engineered vascular constructs 
may be limited by oxygen mass transfer.  This, in turn, could limit the initial mechanical 
functionality and subsequent in vivo function of grafts of clinically relevant size.      
Because of the poor solubility of oxygen in culture media at physiologic temperature, its 
delivery represents one of the most critical issues in engineering clinically relevant 
functional 3D tissues.31 While cells consume approximately six mole of soluble oxygen 
per mole of glucose, the solubility of oxygen in typical culture media is an order 
magnitude lower than the available glucose. As a result, engineered tissues that are more 
than approximately 100-μm-thick and supplied with nutrients solely by diffusion may 
have insufficient oxygen transport to the cells. It has been widely acknowledged that the 
supply of oxygen becomes critically limiting for the in vitro culture of 3D tissues.34 This 
is demonstrated by early studies showing that cellular spheroids larger than 1 mm in 
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diameter generally contain a hypoxic and necrotic center, surrounded by a rim of viable 
cells.35 Similar observations beyond depths of 0.25 mm were reported for hepatocytes, 
osteoblasts and cardiomyocytes cultured on 3D scaffolds under static conditions.36-38 As a 
result, tissue engineered constructs frequently have an inhomogeneous structure 
consisting of a dense layer of cells and extracellular matrix concentrated along the 
periphery, and a necrotic interior region.39 Because engineered blood vessels should be at 
least 0.5 mm in wall thickness, oxygen mass transfer limitations represent a critical 
design issue to be addressed for tissue functionality. 
The metabolic oxygen consumption rate is generally a function of concentration. The 
most common oxygen consumption rate expression (per unit volume per unit time) is the 
Michaelis-Menten equation:  
maxOxygen consumption rate
m
V C
K C
=
+
 
The above equation reduces to zero-order consumption when the available oxygen 
concentration is high (i.e. mC K ) and to first-order kinetics for low oxygen 
concentrations (i.e. mC K ). The zero-order limit is often considered as a reasonable 
approach because the condition mC K is easily met physiologically.  However, in tissue 
engineering, available oxygen quickly depletes and it is equally likely that the condition 
mC K  to be satisfied. In this study the model is tested with all these possibilities 
(Figure 4.9). It is evident that zero-order consumption led to the local oxygen 
concentration to drop to unacceptably low levels, even with 2% PFD. In many instances 
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oxygen delivery to cells is bounded by zero-order and first-order consumption rates in 
accordance with the Michaelis-Menten equation.  
 
Figure 4.9: A plot oxygen partial pressure across the cross section of the scaffold for 
2.5×106 cell/ml density for zero order, Michaelis-Menten and first order kinetics. 
medium flow rate was 40 ml/min. 
Despite oxygen delivery challenges, tissue engineering of vascular constructs have been 
achieved using different bioreactors.10, 14, 29 In many of these instances, the wall shear 
stress due to increased flow rates inadvertently compromised the integrity of the tissue by 
altering cellular responses.  In the present work the use of 2% PFD as oxygen carrier 
allow us to deliver oxygen to tissue constructs at physiologic shear forces and flow rates. 
Further we made use of realistic vascular tissue diameter and wall thickness to model the 
oxygen profile concentration within the engineered tissue. This is expected to improve 
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design optimization in order to ensure long-term viability and functional property 
maintenances for human implantation. 
4.4 Conclusions 
One unsolved problem in tissue engineering is overcoming hypoxia in thick, three-
dimensional engineered tissues, which is caused by the diffusional limitations of oxygen 
in the centre of the scaffold and lack of internal vasculature to facilitate mass transfer.  In 
order to combat this obstacle, a steady state mathematical model was developed to 
simulate transport of oxygen in both the lumen and the tissue space. In this study, a 
mathematical model was developed using PFD as oxygen carrier in 3D tissue engineered 
scaffold. Dissolved oxygen concentration significantly increased in the presence of PFD 
in a culture media. Vascular smooth muscle cell viability was not affected by the presence 
of the PFD and; cell proliferation with PFD was significantly higher than those without 
PFD. Our data suggest that PFD emulsion increase the oxygen tension in 3D tissue 
engineered scaffolds and enhanced oxygen delivery to cells.   
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CHAPTER 
         5     
 
 
5 TISSUE ENGINEERING SCAFFOLDS CONTAINING 
EMBEDDED FLUORINATED-ZEOLITE OXYGEN VECTORS*
 
  
Overview: This chapter provides the use of fluorinated Zeolite particles as oxygen 
delivery vector. Fluorinated Zeolite particles were prepared and examined for their 
ability to dissolve oxygen in aqueous media. The toxicity of these particles was examined 
and embedded into 3D PCU scaffolds. Finally their effect as an oxygen vector was 
investigated by culturing vascular smooth muscle cells on fluorinated Zeolite embedded 
3D PCU scaffolds.   
Summary 
Efficient oxygen supply is a continued challenge for the fabrication of successful tissue 
engineered constructs with clinical relevance. In an effort to enhance oxygen delivery, the 
feasibility of fluorinated-zeolite particles that are embedded into 3D polyurethane 
scaffolds as novel oxygen vectors is reported herein. First, 1H, 1H, 2H, 2H-
perfluorodecyltriethoxysilane was successfully coupled to zeolite framework particles to 
examine the dose-dependent dissolved oxygen concentration. Following this, the 
fluorinated-zeolite (FZ) particles were embedded into 3D tissue engineering polyurethane 
scaffolds. The data demonstrated an even distribution of FZ particles into 3D scaffolds 
                                   
* A version of this chapter is published: Seifu, D.G; Isimjan, T.T; Mequanint, K. (2011) Tissue engineering 
scaffolds containing embedded fluorinated-zeolite oxygen vectors. Acta Biomaterialia 7:  3670–3678 
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without affecting the scaffold porosity and pore sizes. Human coronary artery smooth 
muscle cells (HCASMCs) proliferation on FZ-containing polyurethane (PCU-FZ) 
scaffolds was significantly higher than the control scaffolds (p = 0.05). Remarkably, cell 
infiltration depths on PCU-FZ scaffolds was doubled compared with PCU control 
scaffolds. Taken together, these data suggest the potential of PCU-FZ scaffolds for tissue 
engineering with enhanced oxygen delivery to cells.    
Keywords: Oxygen delivery, 3D scaffolds, zeolite nanoparticles, tissue engineering 
5.1 Introduction 
The biomedical applications of nanomaterials such as drug delivery systems, diagnostic 
imaging agents, and microfluidics are drawing attentions due to the unique features they 
present.1-3 Tissue engineering strategies benefited from advances made in nanomaterials 
specifically on the utility of carbon nanotube scaffolds.4-7 Although progress has been 
made to fabricate engineered tissues in vitro using both conventional and nanomaterials, 
the inability to deliver sufficient oxygen to the growing constructs (due to its poor 
solubility in culture media) remained to be a formidable task.8, 9 This is exemplified by 
early studies showing that cellular spheroids generally contain a hypoxic and necrotic 
center surrounded by a rim of viable cells.10, 11 Similar observations were reported for 
osteoblasts, hepatocytes, and cardiomyocytes cultured in 3D scaffolds under static 
conditions.12-14   
Previous attempts to overcome oxygen transfer limitations in tissue engineering relied on 
perfusion bioreactors where oxygen dissolved in the culture medium diffuses to the 
scaffold’s interior. However, the high flow rate required to maintain adequate oxygen 
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concentration for cell viability often surpasses the shear stress tolerance of the cells.15, 16 
In an alternative, the use of perfluorocarbon (PFC) emulsions as an oxygen carrier in 
tissue engineering has been investigated where the oxygen unloading of PFC emulsion 
was facilitated by the increased surface area provided by the emulsion droplet size.17 In 
spite of the reported encouraging data, the high density of the PFC emulsion meant that 
the droplets could easily settle either in the culture well or in the medium reservoir.18 
This, in turn, implies that PFC emulsions may not be effective oxygen carriers. In view of 
the above, it would be advantageous if the oxygen carrier molecules could be bound to 
the scaffold. In this regard, Harrison and coworkers reported calcium peroxide-based 
oxygen generating particles incorporated into the scaffold to provide a sustained oxygen 
release over an extended period of time.19 The reaction products, namely Ca(OH)2 and 
H2O2  are, however, strong base and strong oxidizing agents respectively, in which the 
drawback could outweigh the benefit. This drawback is exemplified by a recent study 
which demonstrated significant reduction of fibroblast viability when calcium peroxide 
was incorporated to polycaprolactone fibrous scaffolds.20 In addition, the calcium 
peroxide loaded to the scaffold will eventually be depleted making this approach limited 
to short term cultures.   
In this study, a novel approach of enhanced oxygen delivery to cells seeded in 3D 
scaffolds by incorporating fluorinated porous zeolite particles as an integral part of the 
scaffolds is reported.  
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5.2 Materials and Methods 
5.2.1 Preparation of fluorinated-zeolite (FZ)  
Analytical grade chemicals and reagents used for the preparation of FZ were purchased 
from Sigma–Aldrich (Milwaukee, WI) unless otherwise stated and, were used as 
received. Zeolite Y powder was crystallized from a synthetic gel with a molar 
composition of: 4 Na2O : 1 Al2O3 : 6 SiO2 : 200 H2O : 5 (TMA)2O , where (TMA)2O 
designates tetramethylammonium hydroxide (25%, Merck KGaA, Darmstadt, Germany) 
used as a organic template or structural directing agent. The synthetic gel was prepared by 
dissolving appropriate amounts of sodium aluminates (NaAlO2) as Al source and sodium 
hydroxide (NaOH) to a mixture of water and (TMA)2O  under vigorous stirring until a 
homogenous solution was obtained. Silica gel (as Si source) was then added to the 
resulting solution in a 30 ml Teflon reactor and mixed for 10 min. The resulting synthetic 
gel was aged for 48 h under static condition. The zeolite Y product was allowed to 
crystallize from the aged gel at 100oC in an oven for 48 h.  When the reaction was 
completed, the pure crystalline zeolite powders were recovered from the suspension by 
centrifugation at 10,000 rpm. The solid particles were re-dispersed in deionized water and 
centrifuged again. The washing and centrifugation process were repeated three times. The 
solid products were dried at 50oC for 24 h, followed by calcinations at 500oC for 5 h in a 
programmable furnace with the heating and cooling rate of 1oC/min to activate the zeolite 
by removing the organic residues and water. The resulting zeolite-Y was then fluorinated 
with 1 wt % methanol solution of 1H, 1H, 2H, 2H-perfluorodecyltriethoxysilane (PTES) 
for 1 h, filtered and then heated at 140oC for an additional 1 h. The particle sizes of the 
zeolite were in the range of 850 nm-1000 nm. 
   115  
 
5.2.2 Fabrication of PCU-FZ scaffolds 
A medical grade poly(carbonate urethane) (PCU) (Bionate® 55D) was kindly donated by 
the Polymer Technology Group (Berkeley, CA). 3D scaffolds were fabricated by a 
solvent casting and particulate leaching method as previously described21 with some 
modifications. Ground and sieved NH4Cl porogens (180-250 µm) were packed into a 6 
mm diameter cylindrical infiltration chamber together with 2 wt% FZ nanoparticles and, 
the polymer solution (15 wt% PCU dissolved in N,N-dimethylformamide) was 
subsequently poured over the porogen bed and pressurized to infiltrate the porogen bed.  
Following this, the scaffolds were removed from the assembly and the solvent was 
allowed to evaporate in a fume hood. Finally, NH4Cl porogens were leached out using 
deionized water and, the scaffolds were sectioned into 1.5 mm height disks using a 
microtome. This height (or thickness) of the scaffolds was chosen to mimic the 
thicknesses of many soft tissues such as cartilages,22 skin,23 cardiac,24 and blood vessels25 
that are the subject of tissue engineering . Two different control scaffolds, namely PCU 
scaffolds without FZ particles and, scaffolds that contained non-fluorinated zeolite 
particles, were fabricates in a similar way. 
5.2.3 Dissolved oxygen measurement  
Fibre optic oxygen sensor model NeoFox (Ocean Optics, Dunedin, FL) equipped with 
NeoFox software was used to measure dissolved oxygen. The sensor uses ruthenium (II) 
complexes suspended in a support matrix and attached at the tip of the fiber optic cable. 
When excited by a light emitting diode at 475 nm, the ruthenium complex fluoresces and 
emission occurs at 620 nm. When the excited ruthenium complex encounters an oxygen 
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molecule, the emission is quenched allowing the intensity of the fluorescence to be 
related to the oxygen concentration. Accordingly, the more oxygen that is present, the 
lower the emission intensity and vice-versa. In the absence of oxygen, the maximum 
fluorescent intensity of emitted light is observed. FZ nanoparticles at concentrations of 
0.5%, 1%, and 2% were suspended in deionized water and continuously stirred at 37oC 
while the assembly was left open to atmospheric air. Deionized water and non-fluorinated 
Zeolite particles (non-FZ) suspended in deionized water (at 2% concentration) were used 
as controls. A 300 nm diameter oxygen probe was used to measure the dissolved oxygen 
following a two point calibration with 20.9% of oxygen at standard temperature and 
pressure and 0% oxygen in 100% nitrogen.   
5.2.4 Chemical composition and morphological studies of FZ and PCU-FZ scaffolds  
The crystallinity of the zeolite particles was measured by powder X-ray diffractometer 
(XRD),  (Rigaku RINT 2500, Tokyo, Japan) with Cu K radiation (λ = 1.54Å) at 40 kV 
and 50 mA with a scan rate of 0.02 degrees per second over a 2θ ranges of 2° to 40°. The 
zeolite particle pore size and surface area were determined by a BET (Brunauer, Emmett 
and Teller) method using nitrogen adsorption–desorption isotherms by means of an 
ASAP2010 instrument (Micromeritics Instrument Corporation, Norcross, GA). The 
zeolite pore size was also calculated by the advanced Barrett–Joyner–Halenda (BJH) 
method using the adsorption-desorption branches of the isotherms. Prior to these 
measurements, the samples were degassed at 170oC for 24 h in vacuum. To investigate 
the surface and cross-section morphology of scaffolds, high-resolution scanning electron 
microscope (SEM) images were captured using model FIB/SEM LEO 1540XB 
microscope (Carl Zeiss, Oberkochen, Germany) operating at electron beam voltage of 1 
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kV. Scaffolds were affixed on a carbon sample holder and were coated with 4 nm osmium 
vapor before imaging. In addition, energy dispersive X- ray spectroscopy (EDX) was 
used to map the elemental composition and distribution within the scaffolds. Elemental 
compositions of the fluorinated zeolite praticles and the scaffolds were determined by X-
ray photoelectron spectroscopy (XPS, Perkin Elmer, Waltham, MA) and EDX. The XPS 
analyses were carried out with a Kratos Axis Ultraspectrometer using a monochromatic 
Al Kα source (15 mA, 14 kV). 
5.2.5 Scaffold porosity measurements 
Mercury porosimetry measurements were made using an Autopore IV porosimetery 
(Micromeritics, Norcross, GA). Samples of PCU and PCU-FZ scaffolds were cut into 
cylindrical disks with 1.5 mm hight and 6 mm in diameter, before placing in the 
penetrometer. Care was taken to place adequate sample in the penetrometer to achieve 
significantly measurable intrusion volumes while maintaining unimpeded access by the 
mercury to the entire surface of the samples. Prior to mercury intrusion, the penetrometer 
was degassed to approximately 4kPa to remove air from the system. Mercury filling of 
the penetrometer was performed at 3.5kPa. Logarithmically spaced data points were taken 
at pressures ranging from 0.35kPa to 410kPa. An equilibrium intrusion rate threshold was 
set at 0.003 mL/g/s. For purposes of data analysis, the surface tension of mercury and the 
intrinsic contact angle with the scaffolds were taken to be γHg = 480 N/m and θ = 140o 
respectively. Average pore areas were corrected for deformation of the scaffold under 
elevated pressure, as described elsewhere 26. 
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5.2.6 Cell culture on PCU and PCU-FZ scaffolds  
Primary human coronary artery smooth muscle cells (HCASMCs) and smooth muscle 
growth media (SmGM®-2 BulletKit) were purchased from Lonza Walkersville Inc. 
(Walkersville, MD, USA). Cells were cultured according to supplier’s instructions in 
smooth muscle growth media (SmGM®-2 BulletKit), supplemented with 100 units/ml 
penicillin G sodium, and 100 µg/ml streptomycin sulphate (Invitrogen, Burlington, ON, 
Canada). All cultures were maintained in a humidified incubator at 37ºC containing 5% 
CO2. HCASMCs were passaged every 7 days at a split ratio of 1:3 and used between 
passages 4 to 7. Cylindrical scaffolds were affixed to glass coverslips using silicone 
grease, sterilized with 70% ethanol for 30 min and allowed to dry under germicidal UV 
light in tissue culture hood for 30 min. After socking the scaffolds in Hank's Buffered Salt 
Solution (HBSS, Invitrgen, Burlington, ON, Canada), all scaffolds were coated with 
fibronectin (10 µg/cm2; Santa Cruz, CA, USA). Cells were seeded into the interstices 
fibronectin-coated PCU and PCU-FZ scaffolds at an initial cell density of ~3×104 
cells/scaffold.  This relatively low seeding densisty was chosen such that we can verify 
cell infiltration depths into the scaffold interstices without cells outgrowing from the 
scaffold surface as is the case in high-densisty seeding. HCASMCs were cultured for 4 
days, 7 days, and 14 days and the culture medium was exchanged every other day.  
5.2.7 Cytotoxicity assay 
For colorimetric assays of the metabolic activity of viable cells, 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) (Invitrogen, Burlington, ON, Canada) was 
used to quantify cytotoxicity and cell proliferation. MTT salts are reduced to a water-
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insoluble formazan salt only by metabolically active cells allowing the assay to detect 
viable cells exclusively. After it was solubilized, the formazan formed was quantified in a 
conventional plate reader at 570 nm (maximum absorbance). PCU-FZ and PCU scaffolds 
were affixed in 96-well culture plates using silicone grease and sterilized with 70% 
ethanol for 30 min. After drying for 30 min, the scaffolds were soaked in HBSS and 
~3x104 HCASMCs were seeded and cultured for 24 h in a humidified chamber at 37ºC 
containing 5% CO2. After changing the culture media, 10μL of MTT was added to each 
well and incubated for 4 h. Then 100μL of sodium dodecyl sulphate (Invitrogen, 
Burlington, ON, Canada) was added and mixed thoroughly and finally incubated for an 
additional 4 h before reading its absorbance at 570nm using a multiplate reader. Two 
different negative control experiments were carried out: (i) by adding MTT to the culture 
medium only and, (ii) by adding MTT to the scaffolds only to rule out the possibility that 
trapped reagents in the scaffold may contribute to background reading. 
5.2.8 Immunofluorescence staining and laser scanning confocal microscopy 
HCASMCs were fixed at room temperature for 1 h with 4% (w/v) paraformaldehyde 
(EMD Chemicals Inc.) and permeabilized for 10 min in cation free phosphate buffered 
saline (PBS) containing 0.1% (v/v) Triton X-100. Cells were incubated for 1 h at room 
temperature in 1% BSA/PBS containing AlexaTM Fluor 488-conjugated phalloidin (1:50 
dilution), followed by three washes with PBS. DAPI (300nM in PBS; Invitrogen, 
Burlington, ON, Canada) was used to label nuclei. Samples were mounted on slides in 
SHUR/MountTM (TBS®, NC, USA) and analyzed with a Zeiss LSM 410 confocal 
microscope (Zeiss, Canada) equipped with an argon/neon as well as a UV laser. 
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5.2.9 Statistical analysis.  
The results for the dissolved oxygen study were analyzed by analysis of variance 
(ANOVA). Student’s t-test was used to analyze the cytotoxicity of PCU-FZ scaffold and 
proliferation of HCASMC as a function of culture time. For all analyses, significance was 
assigned for p < 0.05. 
5.3 Results and Discussion 
5.3.1 Characterization of fluorinated zeolite (FZ) 
In the biomedical field, the use of particles as contrasting agents in imaging and as drug 
delivery vehicles is an emerging area.1-3 In order to expand their potential application for 
tissue engineering scaffolds with oxygen binding capability, porous fluorinated zeolite 
particles with a pore size of ~7.4 Å and surface area of 750 m2/g were prepared. The 
schematic framework structure of zeolite (Y-type) is shown in Figure. 1A. This zeolite 
was fluorinated with a methanol solution of hydrolyzed 1 wt% 1H, 1H, 2H, 2H-
perfluorodecyltriethoxysilane (PTES) (Figure 5.1B). When PTES is attached on the 
surface of zeolite particles, it forms a monolayer at a temperature of 140oC. The XRD 
patterns of the current particles are presented in Figure 5.1C and, are consistent with 
literature data.27 Furthermore, the fluorination step did not affect the crystalline peaks of 
the zeolite particles.  
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Figure 5.1: (A) Framework structure of Zeolite Y, (B) chemical structure of PTES, 
and (C) XRD pattern of the prepared fluorinated Zeolite Y. 
 
5.3.2 Dissolved oxygen concentration in FZ particles 
Measurements of dissolved oxygen concentration in the presence of different weight 
percentage of FZ particles were conducted in deionized water at 37oC and atmospheric 
pressure using a fiber optic oxygen sensor (Figure 5.2). There was no statistical 
significance between the control (0% FZ) and 0.5% FZ. Similarly, there was no statistical 
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significance in the amounts of oxygen dissolved between 1% and 2% FZ (p<0.05). 
However there was a significant difference between the other groups of FZ contents 
(p<0.05). These data show that by incorporating 2% FZ in deionized water, there was a 
significant increase of dissolved oxygen at 37oC. It seems that there is a minimum 
threshold of 1% FZ that is needed to increase the dissolved oxygen concentration in a 
significant way. On the other hand, when non-fluorinated zeolite particles were 
suspended in deionized water, there was no difference in the amount of dissolved oxygen 
compared with deionized water alone. As will be shown shortly in Table 5.2, 73% of the 
fluorinated molecules that are responsible for dissolving oxygen were located at the 
surface of the zeolite particles which, in turn, were exposed to the bulk liquid. This is 
contrary to conventional fluorinated emulsions where the oxygen is trapped in the core of 
the particle. Consequently, the probe measures total dissolved oxygen concentrations 
present both in water and in the fluorinated particles. Thus the increased oxygen 
concentration is attributed to the presence of 1H, 1H, 2H, 2H-
perfluorodecyltriethoxysilane at the surface of the zeolite particles. Gases are transported 
by perfluorinated compounds due to increased solubility in accordance with Henry's law. 
The increase is attributed due to the existence of loose, non-directional van der Waals 
interactions leading to low cohesive energy densities,28 which facilitates mutual 
solubilization of oxygen in the fluorine compound that is bound to the surface of the 
particles that are embedded in the scaffold. Oxygen solubility also reflects the very low 
intermolecular interactions (fluorine’s low polarizability translates into low van der Waals 
forces) within a FZ monolayer. Unlike a chemical binding situation known in 
hemoglobin, solubilized oxygen can be rapidly and extensively extracted from the 
perfluorinated molecules when needed. Although FZ above 2-wt% could have been 
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theoretically incorporated in our experiments, inclusion of more than 2% particles into the 
scaffolds was not possible because the fabricated scaffolds lacked mechanical integrity.   
  
Figure 5.2: Dissolved oxygen concentrations in de-ionized water at 37oC, in the 
presence of non-fluorinated Zeolite particles, and in the presence of different weight 
percentages of fluorinated Zeolite particles. Oxygen concentrations were measured 
using a fiber optics probe. Data are means ± SD for experiments conducted in 
triplicate. * indicates statistical significance at p < 0.05.  
5.3.3 FZ modified scaffolds characterization 
Tissue engineering scaffolds are required to have high porosity and pore 
interconnectivity, and high surface area to volume ratio for cellular infiltration, matrix 
remodelling, and nutrient transport to take place. Using MicroCT imaging, our group 
have previously reported PCU scaffolds having a porosity of 84%.29 Therefore the effect 
of FZ incorporation on the porosity of PCU scaffolds was examined. Mercury 
porosimeter analysis of both control scaffolds and those incorporating FZ particles 
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showed porosities of 90% (Table 5.1). These results indicate that the pore area and 
porosity of the scaffolds was not affected by FZ incorporation.  
Table 5.1: Mercury porosimetry analysis data for PCU and PCU-FZ scaffolds. 
    
The pore-size distribution obtained from the mercury prosimetry is shown in Figure 5.3. 
It is clearly shown that the addition of the FZ particles did not affect the pore size 
distribution. It also shows that the differential intrusion volume, which is an indicator of 
the scaffold porosity, was the same for both PCU and PCU-FZ scaffolds. The porosity 
data presented in Table 5.1 affirms this observation. The intrusion and subsequent 
extrusion cycles during the mercury prosimetry experiments resulted in negligible 
hysteresis indicating that scaffold compression at the operating pressures was minimal. 
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Figure 5.3: Scaffold pore size distribution obtained by mercury porosimetry for 
PCU and PCU-FZ scaffolds plotted as a function of differential and cumulative 
intrusion volumes 
The SEM images of scaffolds presented in Figure 5.4A-D shows that the pores were 
open, interconnected, and well-defined. This is needed for cell infiltration and 
unrestricted cell-cell communications. All scaffolds had similar pore sizes, ranging from 
50-200 μm which are ideal for many tissue engineering applications. At high 
magnification, the embedded FZ particles (≈1µm size) in the FZ -containing scaffolds are 
evident (see insert in Figure. C) indicating that the salt leaching process did not affect the 
particles whereas, at the same magnification, control PCU scaffolds showed smooth 
scaffold struts and walls. Furthermore, these images show that the FZ particles were 
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uniformly distributed along the struts and walls of the scaffolds without affecting the 
macroporosity of the scaffolds.  
 
Figure 5.4: SEM and EDX analyses of fluorinated Zeolite-modified PCU scaffolds. 
(A) Control PCU scaffolds; (B) FZ-modified PCU scaffolds; (C) high magnification 
images of the struts in FZ-modified PCU scaffolds (inset: high magnification image 
showing the FZ particles); (D) SEM image of the area where EDX mapping was 
undertaken; (E–J) EDX elemental mapping for (E) Al, (F) C, (G) F, (H) O, (I) Si and 
(J) a combination of all elements; (K) EDX spectrum for FZ-modified PCU 
scaffolds. Images were captured using a Zeiss LEO 1530 SEM microscope at 
working voltages of 1 keV for high magnifications and 5 keV for low magnifications. 
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Given that we have used a solvent casting and particulate leaching method to fabricate 
these scaffolds, it is remarkable that the FZ particles were not affected during the NH4Cl 
leaching step in water. This is very likely to be the result of better interfacial adhesion 
between the polymer and the FZ particles facilitating improved entrapment of the FZ 
particles. Strong adhesive forces between a zeolite coating layer and bone biomaterials 
have been recently suggested to their enhanced in vitro performance.30 Additional 
evidences for the successful incorporation and uniform distribution of the fluorinated 
particles into 3D scaffolds came from elemental mapping using EDX (Figure 5.4 E-K). 
The qualitative distribution of Al, Si, and F, which are only expected from the FZ-
modified 3D scaffolds demonstrate this even distribution (Figure 5.4 E-J).  
The elemental compositions of the FZ particles and the scaffolds were further studied 
using XPS. The position of the fluorine 1s peaks at 686.8 eV in the XPS spectrum is 
indicative of fluorine substitution in the SP3 carbon framework. As can be seen in Table 
2, the FZ particles had 40% fluorine and 23% carbon. Because the FZ particles are largely 
inorganic in their composition, the carbon atom is relatively low. The PCU scaffold 
which is used as a control had no fluorine peak at 686 eV and, a carbon atom of 81% is 
considerably high. This is not unexpected since the constituents of PCU control scaffolds 
are only carbon, oxygen, and nitrogen (as hydrogen cannot be detected using XPS). 
However, PCU scaffolds fabricated by incorporating fluorinated zeolite particles had very 
strong fluorine 1s peak with atomic percentage of 29% which was 73% of the fluorine 
found in the fluorinated zeolite particles. XPS results not only indicate the incorporation 
the fluorinated zeolite particles in the PCU scaffolds, but also revealed that most of the 
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fluorinated zeolite were on the surface of the scaffolds which is crucial for oxygen supply 
to seeded cell. 
Table 5.2: XPS analysis of the fluorine content in FZ particles, PCU scaffolds and 
PCU-FZ scaffolds. The numbers in brackets indicate the corresponding binding 
energies. 
 
 
5.3.4 HCASMC growth on PCU and PCU-FZ scaffolds  
In a previous publication from our laboratory,31 it was shown that PCU scaffolds were not 
cytotoxic to HCASMC and, that cells proliferated without any phenotype modulation.32 
In view of this, the current study used PCU scaffolds as controls to evaluate HCASMC 
viability on PCU-FZ scaffolds using MTT assay. Figure 5.5A showed that PCU scaffolds 
incorporating fluorinated zeolite particles had no cytotoxic effect to seeded HCASMC. 
This cytotoxicity data is consistent with literature reports suggesting the biological 
activity of silicate and aluminosilicate zeolites having no cytotoxic effects to cells.30, 33, 34 
The use of zeolite framework as a biocompatible and anticorrosive coating for titanium 
alloy biomaterials demonstrated pluripotent mouse embryonic stem cells having higher 
adhesion and proliferation on the 3D zeolite microstructure surface compared with a 2D 
glass surface, indicating that the zeolite coatings were highly cytocompatible.30 Zeolites 
have also been demonstrated to be a safe oral contrast agent for clinical magnetic 
resonance imaging without significant adverse effects.35 Moreover, zeolites are good 
adjuvant in anticancer therapy,36 improve skin-whitening by inhibiting melanin 
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production in a dose-dependent manner,34 and demonstrated to decrease TiO2-
photosensitized reactive oxygen species in cultured fibroblasts.33 
To examine the effect of fluorinated zeolite incorporation to 3D scaffolds, HCASMC 
proliferation on PCU-FZ scaffolds was investigated. The results presented in Figure 5.5B 
demonstrated that cell number significantly increased for 4 days and 7 days of culture for 
PCU-FZ scaffolds (p<0.05). As an additional control experiment, cells were also seeded 
into scaffolds with embedded non-fluorinated zeolite particles to rule out the effect of 
surface topography due to the embedded particles. No difference compared with PCU 
scaffolds was observed. Given that we have seeded equal number of cells on both 
scaffolds and that both scaffolds were not cytotoxic, the significant increase in cell 
numbers on PCU-FZ indicates that these scaffolds provided an environment conducive 
for cell growth by providing sufficient oxygen.  The apparent decrease is cell number at 
day 4 culture is explained as follows. The data at day 1 reflects the initial seeding density. 
The slight decrease in cell number at day 4 is likely attributed due to cell retention. Then, 
the retained cells started to proliferate which is clearly demonstrated at day 7. Although 
this study suggested an increase cell number for PCU-FZ scaffolds for up to 7 days 
culture, it is not known at this stage if the amount of dissolved oxygen will be sufficient 
to support longer culture times or higher cell seeding density that we have used. Further 
studies will be required to address these possibilities.     
 
 
   130  
 
 
Figure 5.5: HCASMC (A) viability and (B) growth on PCU, PCU-FZ, and PCU-non-
FZ 3-D scaffolds. Data are means ± SD for experiments conducted in triplicate. 
*Indicates statistical significance.  
5.3.5 HCASMC morphology and depth of infiltration on PCU-FZ scaffolds  
In addition to the cytotoxicity and cell growth studies, information on the morphology 
and infiltration depths of HCASMCs on 3D PCU-FZ scaffolds is essential. Labeling for 
F-actin and DNA were used to examine cellular morphology following 4, 7 and 14 days 
of culture. Figure 5.6 shows that HCASMCs attached and spread on both scaffolds 
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regardless zeolite incorporation. At higher magnifications, cells making larger contacts on 
both scaffold surfaces are evident.   
 
Figure 5.6: Confocal microscopy images of HCASM cultured on PCU and PCU-FZ 
scaffolds for 4 days(A, B, G, H), 7 days (C, D, I, J) and 14 days (E, F, K, L). 
HCASMC attached to both PCU and PCU-FZ scaffolds had similar morphologies 
but the cell density appeared to be higher on the PCU-FZ scaffolds. Scale bars: (A), 
(C), (E), (G), (I), (K), 200 μm; (B), (D), (F), (H), (J), (L), 100 μm. 
Given that these images are taken at a single plane (cell seeded side), insight into which 
cells infiltrated to the scaffolds is limited. To visualize cell distribution into the center of 
the scaffold, confocal stacks of images were taken such that each image is separated by 
10 μm from the next. The procedure continued to deeper sections of the scaffolds until no 
more cells were detected. The images collected were then binned  into 4 depth ranges 
namely, 0-50 µm; 50-100 µm; 100-150 µm; 150-200 µm and, the results are presented in 
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Figure 5.7.  Interestingly, cells on PCU scaffolds infiltrated only to about 100 µm 
whereas on PCU-FZ scaffolds, infiltration depths doubled to 200 µm during 7 days of 
culture. Since HCASMCs were seeded only on one side of the scaffolds; the observed 
infiltration depths are unlikely to be due to seeding techniques. Furthermore, both 
scaffolds had similar pore sizes and porosity as measured by mercury porosimetery 
(Table 5.2). Therefore, it is believed that enhanced HCASMCs infiltration and uniform 
distribution on PCU-FZ scaffolds is due to the available oxygen at deeper sections of the 
scaffolds. Since cell growth data (Figure 5.5) showed PCU-FZ scaffolds promoted 
HCASMCs proliferation, infiltration appeared to be driven primarily by localized 
proliferation rather than coordinated cellular migration.  
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Figure 5.7: The effect of FZ incorporation on HCASMC spreading and infiltration 
after 4, 7 and 14 days of culture. (A, B, E, F, K, L) PCU scaffolds; (C, D, G–J, M–P) 
PCU-FZ scaffolds. Orthogonal views of the confocal images are shown at the 
bottom. Scale bar: 200 μm. 
Tissue engineering has been motivated by the need to develop novel treatment options for 
the functional restoration of diseased tissues. Despite this, overcoming the diffusion 
barrier that limits the delivery of essential nutrients is a primary obstacle in the 
development of engineered tissues with clinical relevance. As a result, engineered tissues 
that are more than 100 μm-thick and supplied with nutrients solely by diffusion may have 
insufficient transport to and from the cells37 since the cell microenvironment is dependent 
on both nutrient and oxygen availability within the scaffold and the surrounding medium. 
Because of the poor solubility of oxygen in culture media, its delivery represents the most 
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challenge in engineering functional 3D tissues. While cells consume approximately the 
same molar amount of soluble oxygen as glucose, the solubility of oxygen in typical 
culture media is an order magnitude lower than the available glucose. Conversely, an 
excess of oxygen in the medium surrounding the cells without an appropriate carrier such 
as hemoglobin, achieved by using pure oxygen instead of air or by increasing gas 
pressure induces the presence of free radicals, which are cytotoxic.38 Oxygen delivery 
strategies such as perfusion bioreactors have been the most widely investigated where 
flow-induced hydrodynamic conditions were anticipated to increase the mass transport of 
oxygen without cell and tissue damage.39 However, as stated earlier, the high flow rate 
required to maintain an adequate oxygen concentration for cell viability often surpasses 
the shear tolerance of the cells.15, 16 As an alternative, perfluorocarbon emulsions have 
been studied as a means to deliver oxygen to seeded cells.18, 40 In these studies, the 
perfluorocarbon compound was emulsified and added to cell culture medium. However 
their high density (~1.5 to 2 times that of water) make the emulsified particles to easily 
settle thus limiting their full potential. Further, the surfactant used to emulsify is 
considered to be undesirable.41  
Despite the above-stated research efforts, oxygen transport remains one of the main 
limitations in maintaining cell viability and functionality, thus requiring novel approaches 
to deliver sufficient oxygen. The utility of zeolites for biomedical applications in not 
new,27, 30, 33-36 but the idea that fluorinated zeolites could be used as oxygen vector in 
tissue engineering is a novel concept. In this study, the fabrication of 3D porous PCU 
scaffolds with uniformly embedded fluorinated zeolite particles with oxygen delivery 
potential to cells is demonstrated. Furthermore, it is shown that the dissolved oxygen 
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increased with increased fluorinated zeolite particles in water indicating that the oxygen 
dissolving property of 1H, 1H, 2H, 2H-perfluorodecyltriethoxysilane was not affected by 
chemically immobilizing to the zeolite framework. To enhance oxygen transport to 
encapsulated cells, Roberts and coworkers suspended perfluorooctyl bromide and 
perfluorotributylamine to alginate hydrogels as an oxygen vector.42, 43 Although direct 
comparison with the current study is not possible, their results suggest the perfluoro 
compounds within hydrogel membrane improves effective oxygen diffusivity, ensuring 
cell viability and functionality for the encapsulated spheres over extended culture times.  
5.4 Conclusions 
In this study, zeolite particles were successfully fluorinated as an oxygen vector using 1H, 
1H, 2H, 2H-perfluorodecyltriethoxysilane for tissue engineering application. Dissolved 
oxygen concentration significantly increased in the presence of fluorinated zeolite 
particles. The fluorinated particles were then uniformly embedded into 3D polyurethane 
scaffolds during the fabrication process. Vascular smooth muscle cell viability was not 
affected by the presence of the fluorinated zeolite particles and; cell proliferation on 
PCU-FZ scaffolds was significantly higher than the control PCU scaffolds. Cell 
infiltration depths on PCU-FZ scaffolds was doubled compared with PCU scaffolds. 
Taken together, these data suggest the potential of PCU-FZ scaffolds for tissue 
engineering with enhanced oxygen delivery to cells.   
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CHAPTER 
         6       
       
6 GENERAL DISCUSSION AND CONCLUSIONS  
 
Overview: This chapter provides a general summary of the overall work of this thesis 
with specific objectives as mentioned in chapter 2. The strengths and limitations of the 
work are also briefly summarized with few future work directions. Finally a brief 
summary of the overall significance of vascular tissue engineering is included.       
 
6.1 Summary 
 
The main goal of this study was to increase the supply of oxygen to vascular 
smooth muscle cell seeded on 3D PCU scaffolds. The initial step consisted of fabricating 
3D porous PCU scaffolds using a pressure differential/particulate leaching technique.  
NH4Cl was used as a porogen and different concentration of polymer dissolved in DMF 
was used to fabricate disk and tubular shaped scaffolds. SEM micrographs were used to 
characterize the structures and a diffusion apparatus was designed to measure the 
effective diffusivity using of NeoFox oxygen sensor. The measured effective oxygen 
diffusion coefficient and morphology of the scaffold was used to screen the best scaffold 
for the work in this thesis. This helped for assessing scaffolds fabricated from different 
concentrations of PCU for vascular tissue engineering applications. To improve the 
adhesion of HCASMC on PCU scaffolds, scaffolds were modified by adsorbing 
fibronectin on the surface of scaffold. HCASMC seeded scaffolds were cultured in both 
static and flow conditions. Higher cell infiltration and proliferation were resulted in flow 
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conditions than the static culture controls. This is likely due to an improved oxygen 
supply by convective mass transfer in the cell-seed 3D PCU scaffolds.  
 
PFD was used as an oxygen carrier because of its high oxygen solubility. 
Significant increase in the dissolved oxygen was measured when 2% PFD was emulsified 
in the culture media. Furthermore, PFD was found to have no toxicity and have no 
morphological effect on HCASMCs.  This led us to use PFD as an oxygen carrier 
molecule in the culture medium to improve the supply of oxygen to cell-seeded 3D PCU 
scaffolds.  Moreover, a better understanding could be obtained by modeling the oxygen 
profile in the cell-seeded scaffold and in the lumen both at static and flow conditions with 
and without oxygen carrier. Thus, a mathematical model was developed to simulate the 
oxygen in the cell seeded 3D scaffolds.   
 
Anther novel approach to improve the supply of oxygen to cell seeded 3D scaffold 
was developed by embedding oxygen carrier particles into the scaffold.  Micro size 
Zeolite-Y particles were fluorinated using 1H, 1H, 2H, 2H-perfluorodecyltriethoxysilane 
(PFES) and characterized. The surface characterization showed higher fluorine on the 
surface of the particles. The surface modified particles significantly increased the 
dissolved oxygen in the water at 37oC and had no toxicity to HACSMCs. The fluorinated 
particles were successfully embedded into the skeleton of 3D PCU scaffold without any 
modification to the morphology of the scaffold.   Mercury porosimetry results confirmed 
that the porosity and pore distribution of the scaffolds were not affected. A higher cell 
proliferation and penetration depth were observed when HCASMC cultured on scaffolds 
with embedded fluorinated Zeolite particle than HCASMC cultured on PCU control 
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scaffolds. Thus an improvement on the supply of oxygen to cells seeded on 3D PCU 
scaffolds was successfully achieved by embedding fluorinated particles as an oxygen 
vector.   
6.2 Strengths and limitations  
In this study, three significant and equally important strategies of improving the 
supply of oxygen to the cell seeded 3D scaffolds were demonstrated.1, 2  Previous studies 
to improve the supply of oxygen mainly focused on scaffold materials and architecture. 
For example, the use of polymeric hydrogels has been studied and shown to have an 
improved supply of oxygen but week mechanical properties of hydrogels may preclude 
practical applications.3-5 The use of polyurethane vascular grafts may overcome the 
mechanical properties limitation. Moreover, the porous polyurethane scaffold constructs, 
if fabricated from a non-degradable polyurethane, provide additional mechanical support, 
therefore reducing the in vitro maturation time and avoiding problems associated with 
polymer degradation.6, 7 Microfabrication and microfluidics approaches of fabrication 3D 
scaffold showed improvements in the supply of oxygen but the fabrication methods were 
limited to simple structures and, when it comes to tubular and cylindrical structures, 
fabricating scaffolds with microfabrication approach becomes a complicated matter.8-10 
Although, oxygen carriers and channeled scaffolds are reported to improve the supply of 
oxygen,11-13 the practicality of channeling scaffolds with micro size spacing could reduce 
the mechanical property. Furthermore, to supply sufficient oxygen, the spacing should be 
very small which made it challenging to fabricate. The other strength of the study 
documented in this thesis is the use of adult human coronary artery smooth muscle cells 
which addresses the limitations related to species differences and unreliable data 
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extrapolation from animal cell sources to humans. Given that smooth muscle cell 
behavior is highly dependent on patient age and that elderly patients are in most need for 
CABG, the use of adult cells best matches the clinical reality. 
 
Amongst the significant contributions of this work is the use of diffusion chamber 
to determine the effective diffusivity of scaffolds and use this parameter to screen the best 
scaffold for vascular tissue engineering. Further significant contributions of this study are 
the use of PFD as an oxygen carrier and the modeling of oxygen transfer with or without 
oxygen carrier compounds.  Lastly, for the first time, inert Zeolite particles were 
fluorinated and embedded into 3D scaffolds as an oxygen vector for tissue engineering. In 
summation, this work improves the supply of oxygen to cell-seeded scaffolds using three 
different strategies namely: 
• Convective mass transfer using a perfusion bioreactor,  
• Oxygen carrier molecule in the culture media and, 
• An oxygen vector embedded in the 3D scaffold 
 
The main limitation of this study is that detailed histological studies and Western 
blot analyses for dynamic and static cultures were not done. Due to time constraints some 
studies of the dynamic cultures are also missing. Long-term maturation of the engineered 
vascular graft will lead for successful fabrication of vascular constructs.  Overall this 
study attempted to solve one of limitation of tissue engineering which the supply of 
oxygen to 3D constructs and added significant knowledge to the field.   
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6.3 Future direction  
This study sets the ground work for maturing vascular grafts in new and 
automatically controlled perfusion bioreactors with improved oxygen supply. In addition 
to flow conditions these bioreactors have to ability to simulate the physiological 
environment by inducing mechanical stimulation and different kinds of pulsatile flows. 
The load cells help to measure the applied forces like tensile, pulsatile and compression.   
The use of a bioreactor will facilitate long-term culture to mature grafts, while promoting 
cell distribution, cell proliferation, ECM synthesis and deposition, and tissue architecture. 
Future work to fully explore the extent of proliferation of smooth muscle cells seeded 
onto 3D polyurethane scaffolds, and the ability to switch phenotype in response to growth 
factors and mechanical stimulation is strongly recommended. Future work should also 
include the co-culture of endothelial cells and smooth muscle cells with different growth 
factors and the effect of co-culture in cell differentiation, matrix deposition and behaviour 
of smooth muscle cells at physiological conditions.  
6.4 Significance  
This study paves the way for the use of polyurethane scaffolds for fabricating 
tissue-engineered vascular substitutes with improved oxygen supply. The fact that this 
work was focused on vascular tissue engineering does not preclude the approach to be 
equally applicable to other engineer tissue. In general, the strategies of improving the 
supply of oxygen as documented in this thesis is anticipated to alleviate inhomogeneous 
cell distribution and matrix deposition in 3D cultures and help maturing vascular grafts. 
Matured tissue-engineered grafts have the potential to grow, self repair and self remodel 
and these make them very attractive for the treatment of congenital anomalies in pediatric 
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patients and atherosclerosis lesions in adults without immune-rejection. In addition to the 
obvious clinical use, vascular tissue-engineered constructs can also be used as 
pharmacological models to develop new drug candidates and test their toxicity and 
efficacy.     
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